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ABSTRACT 
INVESTIGATION OF THE REPRODUCTIVE EFFECTS OF CHINESE 
HERBAL MEDICINE IN HUMANS AS MEASURED BY 3D ULTRASOUND 
AND BLOOD SERUM  
Aim: To establish whether Chinese Herbal Medicine (CHM) has any positive effect on 
human endometrial receptivity to embryo implantation. 
Design: A prospective interventional clinical study. The measurements used in this study 
were: serum follicle stimulating hormone (FSH), serum progesterone, endometrial 
thickness (ET), sub endometrial 3D-PDA ultrasound indices; vascularisation index (VI), 
flow index (FI), vascularisation flow index (VFI) and pregnancy outcome. 
Setting: A private London natural female heath practice specialising in treating infertility 
with Naturopathic and Traditional Chinese Medicine (TCM). The study period was 
between November 2005 and April 2008. 
Patient(s): Fifty primary or secondary infertile women who had failed at least two  In 
Vitro Fertilisation (IVF)  treatment cycles (the treatment group) with no pathological 
cause after investigation by infertility specialists and diagnosed as suffering with 
unexplained infertility. In addition, a reference group of fifty normal healthy volunteer 
women (the reference group) randomised and double blinded who received either 
placebo or treatment.  
Interventions: Both the treatment group and the reference group received CHM for three 
menstrual cycles. The reference group on a randomised basis received either CHM or  
placebo. All staff at the clinic and the reference group volunteers were double blinded to 
who received placebo or treatment until the end of the study. 
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Results: The treatment group results indicated that there was a statistically significant 
positive difference between pre and post treatment for all variables examined (p < 
0.001). The reference group results were not as significant but never the less, still 
indicated that the improvement was statistically significant between the two arms 
(treatment and placebo) for all measures, with the exception of sub endometrial FI, 
where there was no significant difference between groups. The number of pregnancies 
achieved in the treatment group at 6 months post commencement of the last patient was 
17 pregnancies, 10 live births, 2 miscarriages and 5 ongoing pregnancies (34% overall 
pregnancy rate).   
Conclusions: The study demonstrated that within the treatment group of 50 failed IVF 
patients CHM did improve all the 6 physiological parameters known to affect endometrial 
receptivity by a statistically significant amount and provided a 34% pregnancy outcome. 
The findings of this study show that administration of CHM did have a positive effect on 
the endometrial receptivity measures used in this study and that the pregnancy rate 
achieved in the treatment group was encouraging, however without a control arm it is 
impossible to attribute the pregnancy rate outcome to treatment or reduced stress from 
the placebo effect of receiving treatment. The study also demonstrated statistically 
significant improvement in treatment arm of the reference group whilst the placebo arm 
showed no significant improvement in the same parameters. None of the participants in 
the study experienced any adverse reactions or side effects from treatment.  
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GLOSSARY 
Angiogenic process. Angiogenesis defines new 
blood vessel growth from existing vessels and is a 
critical component in embryonic development, 
tissue growth, tissue remodelling, and a number of 
pathologies.  
B Mode. Low power, 2D ultrasound scanning 
mode used as the basic scanning in most 
ultrasound today.  
BBT. Short for basal body temperature. The body 
temperature at rest. taken orally, vaginally or 
rectally each morning immediately upon 
awakening and recorded on a calendar chart.  
Biomedicine. The branch of medical science that 
applies biological and physiological principles to 
clinical practice.  
BMUS. The British Medical Ultrasound Society, the 
professional body controlling sonography in the 
UK.  
Calcitonin. A 32-amino acid polypeptide hormone 
that is produced in humans primarily by the 
parafollicular cells (also known as C-cells) of the 
thyroid, and in many other animals in the 
ultimobranchial body.
 
It acts to reduce blood 
calcium (Ca
2+
), opposing the effects of parathyroid 
hormone (PTH). 
CD. Short for cycle day defining where in the 
menstrual cycle a woman is at a particular time. 
Cycle day 1 is the first day of full menstrual 
bleeding.  
CHM. Chinese Herbal Medicine, a collection of 
approximately 5000 naturally occurring medicinal 
substances comprising of plant, mineral and 
animal products. 
CL. The post ovulation corpus luteum, a yellowish 
mass of tissue that forms from the granulosa cells 
in the cavity of a Graafian follicle in the ovary of 
mammals after release of the egg cell. The CL also  
secretes the hormone progesterone.  
CM. Chinese Medicine – the term given to 
encompass all the different varieties of traditional 
medicine practiced in china and now the west. CM 
includes acupuncture, herbal medicine, cupping, 
tui na and many other less popular treatment. 
COGI. World Congress on Controversies in 
Obstetrics, Gynecology & Infertility, an umbrella 
for the ever-growing number of sub-disciplines in 
obstetrics and gynaecology profession. The 
program is especially planned to engage in 
controversial issues in all fields related to 
Obstetrics, Gynecology and Infertility, and is 
devised as a meeting forum for world experts from 
all branches of obstetrics and gynaecology. 
 
Doppler Ultrasound. Doppler ultrasound uses 
reflected sound waves to evaluate blood as it 
flows through a blood vessel. It helps evaluate 
blood flow through arteries and veins in the 
female reproductive system. It can show blocked 
or reduced blood flow in the arteries. 
E2. Also called oestradiol, the principal oestrogen 
produced by the ovary. Responsible for formation 
of the female secondary sex characteristics such as 
breasts; supports the growth of the follicle and the 
development of the uterine lining. At mid cycle the 
peak oestrogen level triggers the release of the LH 
spike from the pituitary gland. The LH spike is 
necessary for the release of the ovum from the 
follicle.  
Endometriosis. A condition in which tissue that 
normally lines the uterus grows in other areas of 
the body, usually inside the abdominal cavity, but 
acts as if it were inside the uterus. Blood shed 
monthly from the misplaced tissue has no place to 
go, and tissues surrounding the area of 
endometriosis may become inflamed or swollen. 
This can produce scar tissue. Symptoms include 
painful menstrual cramps that can be felt in the 
abdomen or lower back, or pain during or after 
sexual activity, irregular bleeding, and infertility. 
Epistemology. Derived from the two Greek words 
epistemon meaning "understanding" and logos 
meaning "word." Epistemology is the science of 
knowledge. Epistemology seeks to find the true 
assumptions that account for reality.  
FI. Flow Index, an index as measured by 3D power 
Doppler ultrasound depicting the amount of blood 
flow in all the vessels within a 3D organ volume 
which originated from the weighted colour values 
divided by the colour values. 
FSH. Follicle Stimulating Hormone – the hormone 
secreted by the anterior pituitary gland in both 
mammalian males and females. In females, FSH 
stimulates the development of ovarian follicles 
(eggs) and the release of oestrogen which helps 
develop the uterine lining. 
Graafian follicle. Ovarian follicles or Graafian 
follicles (after Regnier de Graaf) are the roughly 
spherical cell aggregations in the ovary containing 
an ovum and from which the egg is released 
during ovulation. It consists of an external fibro-
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vascular coat, an internal coat of nucleated cells, 
and a transparent, albuminous fluid in which the 
ovum is suspended. 
ESHRE. European Society of Human 
Reproduction and Embryology. The main aim of 
ESHRE is to promote interest in, and 
understanding of, reproductive biology and 
medicine. It does this through facilitating 
research and subsequent dissemination of 
research findings in human reproduction and 
embryology to the general public, scientists, 
clinicians and patient associations; it also works 
to inform politicians and policy makers 
throughout Europe.  
HSG. A method of taking x-rays while injecting dye 
through the uterine cavity and fallopian tubes. It 
can reveal blocked or dilated fallopian tubes, 
fibroids or adhesions within the uterine cavity, or 
an abnormally shaped uterus. 
ICSI. A form of micromanipulation, involving the 
injection of a single sperm directly into the mature 
egg (oocyte). The process increases the likelihood 
of fertilisation when there are abnormalities in the 
number, quality or function of the sperm. ICSI is 
not recommended for treating fertilisation failures 
the result from poor egg quality. 
IgG. One of many antibodies present in blood 
serum which is usually indicative of a recent or 
remote infection. IgG is most prevalent about 3 
weeks after an infection begins. 
ISNAR. The international Society of Natural Cycle 
Assisted Reproduction. 
ISOUG. Short for International Society for 
Ultrasound in Obstetrics and Gynecology. 
IUI. An assisted reproduction procedure, where a 
small amount of concentrated sperm, first 
"washed" to remove most of the seminal plasma 
that surrounds it, is placed in the uterus through a 
thin plastic catheter that is passed through the 
vagina and cervix.  
IVF. A method of assisted reproduction that 
involves combining an egg with sperm in a 
laboratory dish. If the egg fertilises and begins cell 
division, the resulting embryo is transferred into 
the woman's uterus where it will hopefully 
implant in the uterine lining and further develop. 
IVF may be performed in conjunction with 
medications that stimulate the ovaries to produce 
multiple eggs in order to increase the chances of 
successful fertilization and implantation. IVF 
bypasses the fallopian tubes and is often the 
treatment choice for women who have badly 
damaged or absent tubes. 
LH. Short for luteinising hormone, a protein 
hormone that is secreted by the anterior pituitary 
gland. In women, a surge in LH at mid-cycle causes 
ovulation. For the next 7-10 days LH maintains the 
corpus luteum which synthesises progesterone. 
LMP. Short for last menstrual period. Used to 
establish the date of the start of the last menstrual 
period and therefore position in any given 
menstrual cycle.  
Metaphysics. Metaphysics (Greek words meta = 
after/beyond and physics = nature) is a branch of 
philosophy, and related to the natural sciences, it 
can be identified as the study of any of the most 
fundamental concepts and beliefs about the basic 
nature of reality on which many other concepts 
and beliefs.  
Matrix-metalloproteinase. A member of a group 
of enzymes that can break down proteins, such as 
collagen, that are normally found in the spaces 
between cells in tissues (i.e., extracellular matrix 
proteins). Because these enzymes need zinc or 
calcium atoms to work properly, they are called 
metalloproteinases. Matrix metalloproteinases are 
involved in wound healing, angiogenesis, and 
tumour cell metastasis. 
MHRA. An executive agency of the department of 
health which enhances and safeguards the health 
of the public by ensuring that medicines and 
medical devices work and are acceptably safe.  
Oocyte. A female gametocyte or germ cell 
involved in reproduction. In other words, it is an 
immature ovum, or egg cell. An oocyte is part of 
the ovary development 
Ovulation. The periodic release of an ovum from 
the ovaries (usually from only one ovary). After 
the ovum is released, it travels into the fallopian 
tube, and from there is moved to the uterus. 
Ovulation generally happens approximately two 
weeks into the menstrual cycle. 
PI. Blood vessel pulsatility index, a measure of 
blood flow velocity. Pulsatility index (PI = systolic 
velocity - diastolic velocity/mean velocity (S - D / 
A). 
PID. A Gynaecological condition caused by an 
infection (usually sexually transmitted) that 
spreads from the vagina to the upper parts of a 
woman's reproductive tract in the pelvic cavity. 
PID takes different courses in different women, 
but can cause abscesses and constant pain almost 
anywhere in the genital tract. If left untreated, it 
can cause infertility or more frequent periods. 
Severe cases may even spread to the liver and 
kidneys causing dangerous internal bleeding and 
death. 
 ix 
 
Power Doppler. Power Doppler is a newer 
ultrasound technique that is up to five times more 
sensitive at detecting blood flow than colour 
Doppler. Power Doppler is most commonly used 
to evaluate blood flow through vessels within solid 
organs such as ovaries. 
Prednisolone. It is a corticosteroid drug with 
predominantly glucocorticoid and low 
mineralocorticoid activity, making it useful for the 
treatment of a wide range of inflammatory and 
auto-immune conditions such as asthma, uveitis, 
rheumatoid arthritis, ulcerative colitis and Crohn's 
disease, multiple sclerosis, cluster headaches and 
Systemic Lupus Erythematosus. 
PS. Blood vessel PS is a measure of the amount of 
blood flow in cm/sec.  
RCHM. The Register of Chinese Herbal Medicine 
was set up in 1987 to regulate the practice of 
Chinese Herbal Medicine (CHM) in the UK. The 
RCHM regulates and represents over 400 fully UK 
qualified practitioners of Chinese herbal medicine. 
RCT. Randomised controlled trial, the gold 
standard for medical research and clinical trials. 
Using a blinded or double blinded placebo, 
randomised, control group as a metric to measure 
effects of medicines on the treatment group. 
RI. Blood vessel resistance index, a measure of the 
level of attenuation in blood flow. Resistance 
Index (RI = systolic velocity - diastolic 
velocity/systolic velocity (S-D/S)). 
Sperm. Also referred to as spermatozoa, male 
germ cells (gametes or reproductive cells) that are 
produced by the testicles and that are capable of 
fertilising the female partner's eggs. Cells 
resemble tadpoles if seen by the naked eye. 
TA. Transabdominal ultrasound scan performed 
using the percutaneous approach. Clear water-
soluble warm gel is applied to the skin to help the 
transducer make secure contact with the skin.  
TCM. Traditional Chinese Medicine, a modern 
logical, scientific, standardised form of Chinese 
Medicine defined after the Cultural Revolution in 
1949 and now taught from standard government 
textbooks and a standard curriculum throughout 
medical universities in China and in most TCM 
universities in the U.S.A and U.K. 
TCM Kongress. The worldwide TCM conference 
held in Rothenburg, Germany.  The major forum 
for presenting new findings in the TCM field of 
healthcare. Held annually by the 
Arbeitsgemeinschaft für Klassische Akupunktur 
und TCM  and organized by a group of volunteers, 
the Rothenburg team, and the project 
management WOK.  
TV. Transvaginal ultrasound scanning,  where a 
small transducer that looks like a large pen is used. 
A protective cover is placed over the transducer, 
lubricated with a small amount of gel, and then 
inserted into the vagina. 
UA. Short for uterine artery, the major blood 
vessel which is a branch of the internal iliac artery 
supplying blood to the uterus. 
Vascularity. The amount of blood vessels in a 
given area of tissue or an organ. 
VOCAL . A software package on the GE E8 Voluson 
ultrasound machine for imaging 3D volumes of 
organs. The pre-processing step used in this study 
before the image volumes are transferred to 4D 
viewer for further processing and vascularity 
indices are calculated. 
VI. Vascularisation Index, an index as measured by 
3D power Doppler ultrasound depicting the 
velocity of blood flow in all the vessels within a 3D 
organ volume which originated from the colour 
values divided by the colour values + the gray scale 
values. 
VFI. Vascularisation Flow Index, an index as 
measured by 3D power Doppler ultrasound 
depicting the combined volume and velocity of 
blood flow in all the vessels within a 3D organ 
volume which originated from the weighted 
colour values divided by the colour values + the 
gray scale values.  
WNHP. The Women’s Natural Health Practice, a 
naturopathic fertility, gynaecology and obstetric 
clinic located in Harley Street. London and 
Richmond, Surrey. UK. 
3D-PDA. Three dimensional power Doppler 
angiography,  defining the blood flow volume and 
velocity in a matrix of blood vessels inside an 
organ or partial organ. 
Xenobiotics. Chemicals found in organisms, but 
not expected to be produced or present in them; 
or they are chemicals found in much higher 
concentrations than is normal.
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C h a p t e r  I  
INTRODUCTION 
1.1 Background 
Between 10 and 15% of couples have difficulty conceiving at some time in their 
reproductive life according to (Gnoth et al., 2005, p.1144-1147). The most recent 
research indicates a 9% prevalence of infertility worldwide with 56% of infertile couples 
seeking medical care. These estimates are remarkably similar between more and less 
developed countries (Boivin et al., 2007, p.46-47). It has been estimated that at some 
time in their reproductive lives at least a quarter of UK couples experience a period of 
infertility (inability to conceive) lasting over 1 year (Gunnell & Ewings, 1994, p.29-35).  
Fertility declines with advancing years in women and to a lesser extent in men, (Stovall 
et al., 1991, p.33-36) suggests that there is a steady decline in female fertility with age. 
However, more recent research shows that female fertility does not steadily decline as 
previously thought, but follows a gradual linear decline from menarche and at around 
37 years of age the decline becomes more pronounced, but is still linear until 
menopause (Faddy et al., 1992, p.1342-1346, Faddy, 2000, p.43-48). This accelerated 
decline in female reproductive capacity later in life results in proportionally more 
women in the 3rd and 4th decade of life experiencing primary and secondary infertility. 
Many couples in this age group are unable to conceive even after 2-3 years of actively 
trying to conceive, leading to at least 1 in 6 couples seeing an infertility specialist (Hull 
et al., 1985, p.1693). After assessment by a specialist, many couples can be reassured 
that they do not need treatment, just more time with regular sexual intercourse as the 
average time to conceive in the late 30’s is 24 months (Evers, 2002, p.151-159), the 
others will require some form of treatment to assist with conception. 
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The most publicised and well known assisted reproduction treatment (ART) is IVF, but 
there are a number of more natural options, including diet and life style modification 
and a range of less and more sophisticated medical treatment options than IVF. The less 
publicised ART treatments used today are: Ovulation Induction giving 7.4% success per 
treatment cycle, Intra Uterine Insemination (IUI), giving 15.3% success per treatment 
cycle and Intra-Cytoplasmic Sperm Injection (ICSI), giving 25.7% success per treatment 
cycle. Whilst IVF gives 23.4% success per treatment cycle (Human-Fertilisation-and-
Embryology-Authority, 2007).  
The majority of investigated couples will be found to have a pathological male or female 
factor explaining their inability to conceive, 10-25% will be labelled as having 
“unexplained infertility” (Hull et al., 1985, p.1693) and the women over 35 years of age 
attending fertility clinics are twice as likely to experience unexplained infertility as those 
under 35 years of age (Maheshwari et al., 2008, p.538-542). Female unexplained 
infertility is thought to have three causes, diminished ovarian reserve, disorder of 
oogenesis and suboptimal endometrial receptivity (Raine-Fenning et al., 2004, p.2605-
2614). Unexplained infertility is also diagnosed in failed IVF or ICSI cycles which means 
the embryo(s) fail to implant in the uterine cavity lining membrane (endometrium) it 
follows, therefore that sub-optimal endometrial receptivity is one cause of failed ART 
cycles and therefore it is logical to assume that improved endometrial receptivity 
should lead to improved implantation, pregnancy rates and reduced early miscarriage 
rates.  
Couples who fail multiple IVF/ICSI cycles are diagnosed with unexplained infertility and 
come to the end of conventional medicine fertility treatment options and often seek 
complimentary medicine help. The more common complementary medicine systems 
used to treat infertility in the UK today are acupuncture, homeopathy and herbal 
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medicine, although there are many other less well known complementary medicine 
treatment modalities also used to treat infertility. This study is concerned with 
investigating one of the more commonly used complementary medicine treatments, 
herbal medicine and in particular, Chinese Herbal Medicine (CHM) therefore there will 
no further discussion of the other complementary medicine modalities in this thesis. 
Very little evidence based research exists in the West on the effectiveness of Chinese 
Herbal Medicine (CHM) in treating human female infertility. However, there is common 
acceptance of the high success rates possible in treating many types of female infertility 
within The Peoples Republic of China 中華人民共和國 (PROC) which is based on 
thousands of years of empirical clinical success. A great deal of research has been 
published in Chinese language and is available in the PROC on this subject but most is 
inaccessible in the West due to the language barrier and limited translations. It is also 
questionable whether many of the studies published in the PROC would be credible and 
accepted as evidence based medicine in the West today. Discussing this issue further is 
outside the scope of this study.  
 
An urgent need therefore exists for original evidence based CHM infertility research to be 
carried out in the West which conforms to accepted scientific research standards in order 
to build a knowledge base upon which credibility for CHM can be established. In order to 
be credible the results must be adequate to be published in reputable peer reviewed 
journals. The research must focus on investigating both the efficacy and safety of CHM in 
treating female infertility as well understanding the interaction between herbal 
medicines and conventional pharmaceutical medicines. If the findings are positive 
regarding efficacy and safety this would lay the foundations for eventually integrating 
conventional and complimentary medicine infertility treatment and establishing 
  4 
 
credibility within the conventional medicine community which will hopefully lead to 
wider and deeper evidence based research being carried out by conventional medicine 
researchers.  
 
The potential benefits of integrating conventional and CHM could be enormous in terms 
of reduced drug costs, reduced side effects and most importantly, improving success 
rates. The MSc pilot study carried out by this researcher in 2004 highlighted significant 
improvements in the endometrial thickness (ET) and uterine artery (UA) blood flow as 
well as improvements in ovarian folliculogenesis. It was therefore logical to focus this 
follow-on study on researching deeper into either ovarian folliculogenesis or endometrial 
receptivity, both significant studies in their own right. Given that the group this 
researcher decided to study was failed IVF patients and that this group of women 
undergo routine ovarian stimulation as part of their IVF treatment to produce increased 
follicles, yet have no little or no treatment to improve the receptivity of the endometrium 
to implantation it was this aspect of the results from the pilot MSc study that seemed to 
be most important to investigate further. 
 
The recent arrival of a new generation of digital high resolution diagnostic ultrasound 
machines using three dimensional power Doppler angiography (3D PDA) means a 
reliable, repeatable measurement mechanism now exist for the first time to scientifically 
measure the physiological effects of medicines (including CHM) on ovarian function and 
blood perfusion in the endometrium. This has previously been proven to be an important 
aspect of embryo implantation (Raine-Fenning et al., 2004, p.2605-2614) and is assessed 
by measuring sub-endometrial vascular perfusion of the endometrium in a simple, non-
invasive way. This study makes use of these latest ultrasound diagnostic techniques, 
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specifically 3D PDA, together with serum hormone assays to assess the effects of CHM on 
endometrial receptivity. 
 
1.2 Study research goals 
The research study goal is to establish whether CHM improves endometrial receptivity to 
embryo implantation.  The two research questions to be answered by this study in 
pursuit of this goal are:  
1) To what extent does CHM affect the endometrial receptivity of normal 
healthy women? 
 
2) To what extend does CHM affect the endometrial receptivity of women with 
unexplained infertility who fail in IVF treatment?. 
 
The group of infertility patients most commonly seeking treatment using CHM today are 
failed IVF/ICSI patients as for most this is a last chance to achieve a pregnancy with their 
own eggs. Therefore we have decided to study this particular subgroup of the female 
infertility population. In addition, because CHM effects on endometrial receptivity has 
never been studied before we have decided to also study normal healthy women in 
parallel to establish baseline reference data for healthy women. 
 
1.3 Study measurements 
The following six measurements have been selected as the most appropriate 
physiological measurements of endometrial receptivity and will be fully discussed in the 
following literature review chapter of this thesis. The relationship between endometrial 
receptivity and the six measurement parameters used in this study and their relevance to 
the study results are discussed below.  
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The six physiological measurement parameters are: 
1) Serum Follicle Stimulating Hormone (FSH). 
2) Endometrial thickness. 
3) Sub endometrial blood flow (VI, FI and VFI). 
4) Serum progesterone. 
 
1.3.1 Follicle Stimulating Hormone (FSH) is the first hormone produced at the 
beginning of each menstrual cycle. It is produced in the anterior pituitary gland at 
the base of the brain, itself under the control of Gonadatrophin Releasing Hormone  
(GnRH) from the hypothalamus. The normal levels for FSH at the beginning of the 
menstrual cycle are between 4 IU/L and 12 IU/L. The main function of the ovaries is 
to develop follicles containing oocytes, called antral follicles and to mature (usually) 
one of these follicles in each menstrual cycle into a Graafian or dominant follicle 
which will become the ovulatory follicle. The degree to which an ovary is able to 
achieve this folliculogenesis and maturation is determined firstly, by the ovarian 
reserve of primordial follicles and the occyte quality (both are age related) and 
secondly by the ovarian blood supply. A healthy arterial blood supply is needed to 
transport FSH from the pituitary gland to the ovaries to stimulate the ovaries and 
start the antral follicle maturation process. Arterial blood supply is also needed to 
nourish the developing follicles which require more and more arterial blood as the 
number and size of follicles increase during the first and second week of the 
menstrual cycle. Healthy venous blood return is also needed to facilitate the 
transport of oestradiol secreted from the developing follicles and provide the 
feedback to the pituitary to reduce FSH secretion. In a female its role in the 
hormone symphony that is the menstrual cycle is to ‘wake up’ the ovaries and 
stimulate follicle development. The ovarian response is to start recruiting 
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primordial follicles and maturing them into antral follicles on each ovary. As they 
develop they release oestradiol into the blood system in increasing amount 
through the follicular phase of the menstrual cycle from granulosa cells within the 
developing antral follicles. The resulting serum oestradiol level is proportional to 
both the number and size of developing follicles with the increasing amount of 
circulating oestradiol acts as a negative feedback on anterior pituitary gland 
function thereby attenuating ovarian follicle growth and oestradiol levels. FSH 
then, is a well recognised measure of ovarian response to pituitary stimulation and 
the lower the FSH levels are the stronger and more healthy the ovarian activity and 
so oestradiol levels. In peri-menopausal women FSH is elevated and oestradiol 
reduced signifying reduced ovarian response to FSH stimulation.  The higher the 
oestradiol levels the higher the stimulatory effect on endometrial tissue resulting in 
a higher quality endometrium and improved endometrial receptivity. There have 
been many previous studies of FSH levels and pregnancy outcomes in sample 
groups of women undergoing IVF treatments showing women with lower FSH 
levels require less stimulation and achieve higher pregnancy rates.   
 
1.3.2 Endometrial thickness - The endometrium is particularly important in female 
fertility as failed IVF and ICSI cycles are mainly associated with factors effecting 
implantation and trophoblastic invasion of the embryo into the endometrium. It 
has been well established by previous workers that an increasing endometrial 
thickness is associated with increasing pregnancy rates in IVF cycles and pregnancy 
rates were found to be highest when the endometrium reached at least 10 mm 
(Kovacs et al., 2003, p.2337-2341). Furthermore, it has been proven that an 
endometrial thickness of < 7 mm will not result in a sustained pregnancy during IVF 
cycles (Glissant et al., 1985, p.786, Steer et al., 1992, p.372-376). It is now 
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becoming accepted that an endometrium of between 10-15 mm is desirable for 
best chances of implantation and sustained pregnancy and reduced chance of early 
miscarriage. For patients with marginal endometrial thickness even small changes 
are significant factors in increasing the probability of a natural pregnancy. In 
assisted conception treatment clinicians now recognise that endometrial thickness 
does influence success rates and some clinics now routinely evaluate endometrial 
thickness as part of their standard range of pre treatment diagnostic tests. In 
general, however there is still not sufficient focus given to the role of endometrial 
quality within IVF cycles. With several evidence based studies into endometrial 
quality and IVF outcomes already published and still more underway this will 
hopefully change in the future.  
 
1.3.3 Sub Endometrial Blood Flow - The increase in follicle numbers and Graafian 
follicle size directly correlates with a rise in circulating oestradiol. The main function 
of which is to develop the endometrium in preparation to receive a fertilised ovum 
at around 7-9 days post ovulation. Oestradiol is transported to the endometrial 
tissue facilitating the proliferation of the endometrium via the left and right uterine 
arteries; blood flow is then distributed within the uterine myometrium to the sub 
endometrial level via the uterine arcuate artery vascular network. Therefore 
measuring the volume of blood flow and the velocity of blood flow in the sub 
endometrial capillary network is an extremely good indicator of endometrial 
receptivity and has been shown to be significantly higher in normally fertile women 
and lower in women with unexplained infertility (Raine-Fenning et al., 2004, 
p.2605-2614). Measuring sub endometrial vascularity using 3D PDA with the 
indices of FI, VI and VFI is the most sophisticated method of reliably assessing total 
aggregated flow and aggregated velocity of the entire sub endometrial vascular 
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network available today. The normal levels of VI,FI and VFI cannot be expressed yet 
in absolute levels as they are dependent on the sensitivity of the ultrasound 
machine Power Doppler hardware (Ritchie et al., 1996, p.277-286). From the work 
by Raine-Fenning et al (2004), we know that sub endometrial VI, FI and VFI are all 
reduced by 50-60% in sub fertile women compared to normal women and that an 
increase in these indices reliably shows an increase in sub endometrial vascular 
network blood flow and therefore receptivity to embryo implantation. 
 
1.3.4 Progesterone - In the luteal phase of the menstrual cycle ovarian arterial 
blood supply is needed to nourish the highly vascular corpus luteum and the 
venous return to facilitate transport of progesterone from the corpus luteum to the 
uterus to maintain the spiral arteries and a secretory endometrium and support 
early pregnancy until the placenta is established and takes over progesterone 
production. The normal level of progesterone in the mid luteal phase of the 
menstrual cycle is between 4 nmol/L and 86 nmol/L (Stavreus-Evers et al., 2001, 
p.782-791). Once ovulation has taken place and fertilisation has occurred (usually) 
in the ampulla of the fallopian tube and the endometrium has been prepared by 
circulating oestradiol sufficiently to support an implantation maintaining the 
secretory endometrium is achieved by the effect of progesterone produced in the 
corpus luteum. Progesterone is at its highest level 6-8 days post ovulation 
(CD20,21,22 in a normal 28 day cycle). This is measured by serum blood levels with 
the blood draw being taken 6-8 days after ovulation has been confirmed. 
Progesterone raises very rapidly immediately post ovulation and attains its apogee 
in the mid luteal phase then rapidly decreased in the few days before onset of 
menses as the corpus luteum degenerates and progesterone becomes insufficient 
to sustain the endometrial spiral vessels supply initiating menstrual bleeding and 
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endometrial shedding. During IVF cycles it is common to support the transferred 
embryos with supplemental progesterone usually given in the form of a vaginal or 
rectal pessary (cyclogest). Whilst there are little or no side effects from this 
treatment synthetic progestin probably is not as bio available as endogenous 
progesterone and therefore, as effective in supporting pregnancy compared to 
endogenous progesterone from the corpus luteum. Research has shown that the 
luteal phase is defective in virtually all stimulation protocols used in IVF. LH 
supports the corpus luteum function and LH levels have been found to be reduced 
in human menopausal gonadotrophin (HMG) , gonadotrophin-releasing hormone 
(GnRH-agonist/HMG) and GnRH-antagonist/HMG  stimulation protocols, resulting 
in insufficient corpus luteum function (Tavaniotou et al., 2002, p.123-130). Work 
has already been done to prove an association between corpus luteum vascularity 
and progesterone levels and higher progesterone levels are correlated with 
increased corpus luteum size and increased vascularity (Wing & Sedlmeier, 2006, 
p.26-32). More research is needed to understand the relationship between LH and 
progesterone in the luteal phase of IVF cycles and whether CHM has any 
therapeutic role in improving implantation rates via improved corpus luteum 
function during IVF cycles. However, what we do know is that progesterone is 
essential to maintaining spiral artery function and endometrial vascularity and so 
any increase in progesterone levels will have a positive effect on endometrial 
receptivity. 
 
1.4 Study hypothesis 
The hypothesis for this study is “CHM does improve endometrial receptivity and 
therefore increase pregnancy rates”. The measurements selected to be used in this study 
are; uterine endometrium thicknesses, sub endometrial vascularity, serum FSH and 
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progesterone levels. Conversely the null hypothesis is that administering CHM has no 
statistically significant effect on endometrial receptivity or pregnancy rates. 
 
1.5 Research aims and objectives 
i. Establish a sample group of 50 failed IVF patients registering for treatment at 
The Women’s Natural Health Practice. This group is referred to as “the 
treatment group” to be treated with individualised CHM formulas in capsule 
form in the traditional way infertility patients are treated using TCM. 
 
ii. Establish a second sample group of 50 healthy female volunteers to provide 
baseline reference data for normal women. This group were randomised into 
a CHM treatment arm” (n = 25) and a placebo arm (n = 25) and are referred to 
as “the reference group”. This group was a double blinded receiving 
individualised CHM formula or ground rice placebo. 
 
iii. For both the treatment and reference groups test and record a set of 6 
measurements before treatment related to endometrial receptivity one at the 
beginning of the menstrual cycle (CD1 or 2) and the remainder at 7-9 days 
post ovulation (Endometrial thickness, Sub-endometrial 3D angiography blood 
flow (VI, FI, VFI) and serum FSH and progesterone level). 
 
iv. Administer individualised formula Chinese Herbal Medicine capsules to the 
treatment group and either, individualised formula Chinese Herbal Medicine 
capsules or placebo capsules to the reference group for three menstrual 
cycles.  
 
v. Retest the same parameters at the same time in the menstrual cycle for both 
groups in the 3rd menstrual cycle of treatment and also follow up each 
treatment group patient monthly for a further three months to determine if a 
subsequent pregnancy is achieved. 
 
vi. Analyse the results and discuss findings. 
 
vii. Draw conclusions and make recommendations for change of practice and 
make suggestions for further related studies. 
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C h a p t e r  I I  
LITERATURE REVIEW 
2.1 Background 
Infertility is a major cause of distress to for couples and particularly so where the woman 
is in the 3rd and 4th decade of her life when egg quality rapidly declines as shown by 
(Faddy et al., 1992, p.1342-1346, Faddy, 2000, p.43-48). The reasons for this increasing 
infertility prevalence are now well understood and many more women are now waiting 
longer before attempting to conceive while they develop their careers which further 
compound the prevalence of infertility. In addition, as sexually active women grow older, 
the likelihood that they might be exposed to infertility causing sexually transmitted 
infections increases, specifically the recent increase in the incidence of Chlamydia in 
women of reproductive age (Health-Protection-Agency, 2007) which showed a 150% 
increase since 1998 and an annual increase rate of 7% per year among UK women. The 
infections responsible for female infertility are in many cases asymptomatic but can 
permanently damage the female reproductive organs dramatically reducing a woman's 
ability to conceive. As a woman ages her egg (oocyte) quality decreases (Fig 1) and since 
many women are delaying starting a family until they are in their late 30s or early 40s, 
infertility has become a very common and growing condition. About one-third of women 
who defer pregnancy until their mid-30s will have a problem becoming pregnant and 
most women over age 40 today will have significant problems conceiving (Office-for-
National-Statistics, 2007).  
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Fig 1, Follicle attrition with age, showing that female fertility declines at a linear rate until mid 
to late 3
rd
 decade then sharply declines until menopause.  (Faddy et al., 1992, p.1342-1346, 
Faddy, 2000, p.43-48). 
 
At puberty the human female reproductive system becomes functional and reaches it’s 
zenith in terms of fertility when a woman is in her late 20’s with the average woman 
reaching peak fertility by age 30 and by age 50 (average age of menopause in the U.K.) 
she has almost no ovarian function remaining as shown by (Velde & Brooekmans, 1999, 
p.79-79).  There are dramatic changes in menstrual function and fertility in a woman in 
her 5th decade, for most women the first change is the monotrophic rise in follicle 
stimulating hormone (FSH) which is usually accompanied with shortened follicular phase 
of her menstrual cycle leading to a decreased menstrual cycle length (usually 3-5 days 
shorter). These shorter cycles are often referred to as the climacteric phase of a woman’s 
reproductive life. Progression toward menopause is then characterised by profound 
decrease in fertility and dramatically irregular menstrual periods occurring in a random 
fashion (Velde & Brooekmans, 1999, p.80-80) showed that menstrual cycles at this time 
comprise of both ovulatory and non-ovulatory cycles and are often accompanied by 
vasomotor hot flushes and premenstrual symptoms. Termed the peri-menopause this 
phase usually lasts for 3-4 years, according to (Sonja, 1992, p.37-46). The menopause is 
reached clinically when a woman is 12 months past her last menstrual period, with the 
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average age at menopause being 50-51 years, however the 95% confidence interval is 
relatively large at 42-60 years (Velde & Brooekmans, 1999, p.80-80). 
 
2.2 Causes of infertility 
Ageing is not the only cause of female infertility seen and ageing is not classified as 
pathological, rather the normal, naturally occurring fertility decline. For women of any 
reproductive age pathology can also result in a couple experiencing primary (never 
conceived previously) or secondary (conceived previously but unable to conceive 
subsequently) infertility (Fig 2). It is the combination of women waiting later in life to 
start their families and the addition of pathology that is leading the majority of women 
who seek fertility treatment in the U.K. being in the 3rd and 4th decade of their life. 
 
 
Fig 2,  Causes of infertility, (Evers, 2002, p.151-159) 
 
Whilst pathological causes account for 72% of infertility causes seen in tertiary care for 
26% of couples there will be no known pathological cause and they will be given the 
diagnosis of unexplained infertility. The most common non-age related pathological 
causes of couple infertility are: Male factor (poor sperm quality and/or quantity), 
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Ovulation (anovulation), Cervical mucus (low oestrogen or abnormal pH cervical mucus 
immobilising or preventing sperm entering the uterus) and Tuboperitoneal (a 
combination of dysfunctional fallopian tubes and/or endometriosis). Usually only one 
cause is identified at investigation but in some cases there can be multiples of these 
causes (Fig 2).  
 
Table 1, Relative percentage of causes of infertility diagnosed at primary, 
secondary and tertiary care (note: other is couple incompatibility in the 
most part).     (Evers, 2002, p.151-159). 
 
 
A recent study published in the Lancet collected data on the prevalence of infertility 
causes at primary, secondary and tertiary care defining five causes discussed above 
(Table 1). The study found that male factor remained reasonable constant at each stage 
of care indicating little could be done to treat this cause. Ovulatory dysfunction is well 
treated with biomedicine and by the time patients arrive at tertiary care this cause has 
reduced from 24% to 18%. Cervical mucus is misleadingly shown to become 0% by 
tertiary care because at tertiary care mucus is not assessed at all as it is bypassed by 
assisted reproductive treatments (Evers, 2002, p.151-159) . In a recent study (Suarez & 
Pacey, 2006, p.23-37), it was found that the cervical mucus is affected mainly by altered 
cervical mucus oestrogen or pH levels resulting in a poor environment for sperm 
transport and survival and that previous cervical surgery such as cone biopsy also reduces 
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mucus production. Tuboperitoneal increases from 11% to 30% as this aspect of female 
infertility cannot usually be investigated until arrival at tertiary care and is, in any case, 
untreatable in primary and secondary care and disappointing levels of treatment success 
at tertiary care. Unexplained infertility interesting decreases between primary and 
secondary care, this is because with more sophisticated investigation at secondary care 
many of the unexplained cases are diagnosed subsequently as pathological.  
 
The Evers (2002) study, however, showed no reduction in diagnosis of unexplained 
fertility between secondary and tertiary care indicating no further additional insight or 
treatment offered demonstrating the clear need for further research into unexplained 
fertility. Unexplained infertility is the most promising and potentially the most fruitful 
area of research and treatment for complementary medicine because biomedicine as yet, 
has no treatment to offer this group of patients where as complementary medicine has 
demonstrated encouraging levels of success in treating unexplained infertility, albeit 
empirically. The holistic nature of diagnosis of complementary treatment achieves good 
levels of success in the unexplained infertility category as demonstrated by Wing & 
Sedlmeier (2006). One known major cause of unexplained infertility is related to poor 
endometrial receptivity causing implantation failure which was researched by (Sharkey & 
Smith, 2003, p.289-307) and also identified as a cause of early pregnancy miscarriage in a 
separate study by (Rana et al., 1997, p.S100).  
 
Given endometrial receptivity is the subject of this study, the focus for the remainder of 
this literature review will be endometrial receptivity as a cause of unexplained infertility 
and failed IVF cycles.  The other causes of couple infertility will not be elaborated on or 
discussed further to any great extent. The reduced uterine artery flow levels or high 
resistance uterine blood flow has been associated with impaired endometrial receptivity. 
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Recent studies into changes in uterine artery blood flow and their effect on implantation 
have shown a strong positive correlation between low flow rates and high resistance in 
the uterine arteries in the peri-ovulation period resulting in reduced implantation rates 
(Chien, 2004, p.496-500). Another important related finding by Habara et al (2002)., 
demonstrated elevated blood flow resistance in uterine arteries in women with 
unexplained habitual early miscarriage rates which established the connection between 
failed IVF implantation failures and early miscarriage both being caused by reduced blood 
flow in the uterine arteries.   
 
3D PDA has provided some exciting and promising insight into understanding 
endometrial receptivity. This is because 3D PDA collects and analyses endometrial and 
sub endometrial blood flow in even microscopic capillary vessels inside the uterus and 
provides an index metric measurement for the entire vascular flow within the various 
tissue types (Raine-Fenning et al., 2004, p.330-338). Previously only the blood flow into 
the uterus at the point of the uterine arteries could be measured with 2D ultrasound 
power Doppler which was unable to detect any abnormalities in blood distribution or 
perfusion inside the uterus or endometrium. 
 
2.3 Conventional medicine treatment 
Conventional medicine treatment for female infertility uses two approaches. Firstly, 
either surgical or drug treatment to correct the pathological factor and secondly, by 
bypassing the pathological factor when it is difficult or impossible to treat (such as 
bypassing blocked fallopian tubes). The most common conventional medicine infertility 
treatments used today are: Ovulation Induction, IUI, IVF and ICSI (Human-Fertilisation-
and-Embryology-Authority, 2007). 
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2.3.1 Ovulation induction  
Ovulation induction uses pharmacological medications to trigger ovulation. 
Different drugs are used to overcome the different conditions which can cause 
the failure of the ovaries to release eggs. The most common groupings include 
drugs which stimulate the pituitary gland and drugs which act directly on the 
ovaries themselves such as clomifene citrate (clomid). The live birth success rate 
using ovulation induction treatment is reported by the UK controlling body for 
assisted conception (the HFEA) was 7.4% per treatment cycle (Human-
Fertilisation-and-Embryology-Authority, 2007) and is only successful where 
anovulation has been confirmed to be the cause of infertility. 
 
2.3.2 Intra Uterine Insemination 
IUI is a simple fertility treatment with a good track record of success with women 
whose tubes are healthy and their partners produce fertile sperm. The chances of 
conception taking place are increased by inserting washed and prepared sperm 
into the womb at the time the ovaries release an egg. It is usually employed in 
conjunction with the woman taking ovarian stimulation drugs. The sperm is 
prepared so that the healthiest specimens can be selected. The live birth success 
rate using this treatment is 15.3% per treatment cycle (Human-Fertilisation-and-
Embryology-Authority, 2007) but requires normally functioning fallopian tubes 
and ovulatory cycles.  
 
2.3.3 In Vitro Fertilisation 
In Vitro literally means 'in glass' and it explains why these children have come to 
be known as test tube babies. The woman takes fertility drugs to increase the 
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number of available eggs (ovarian stimulation). The purpose of ovarian 
stimulation is to encourage the ovaries to produce more accessible eggs than the 
usual single egg in a normal monthly cycle. Allowing multiple selected high 
quality embryo’s to be placed in the uterus thereby maximising pregnancy rates. 
The live birth success rate using this treatment is 24.3% per treatment cycle 
(Human-Fertilisation-and-Embryology-Authority, 2007). 
 
2.3.4 Intra-Cytoplasmic Sperm Injection 
ICSI is one of the latest techniques is used in the treatment of male infertility. It is 
used where the sperm count is extremely low, sperm motility is poor or there is a 
high percentage of abnormally shaped sperm or multiples of these factors. It is 
also used for cases where sperm has been surgically collected from the man 
because of an anatomical or pathological obstruction or failed vasectomy 
reversal. With ICSI a single selected sperm is injected directly into the centre or 
cytoplasm of an egg and one or more embryos are then placed in the womb in 
exactly the same way as with IVF treatment. The live birth success rate of this 
treatment is 25.7% per treatment cycle (Human-Fertilisation-and-Embryology-
Authority, 2007). 
 
2.3.5 Response to conventional medicine fertility treatment 
Unfortunately, not all women respond to the ovarian stimulation used in 
convention medicine IVF treatments the same way. Predicting ovarian 
stimulation response is achieved by measuring the female sex hormone levels, 
oestrogen (oestradiol) and FSH or anti-mullerian hormone (AMH) or Inhibin B on 
the first or second day of a woman's menstrual cycle (Hansen et al., 2008, p.699-
708). Elevated FSH (and or decreased Inhibin B or AMH levels) indicate a more 
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rapid decline in normal, available oocytes than would be expected for a woman’s 
age. A woman with elevated day 1/2 FSH level has been shown to have a much 
lower likelihood of responding to fertility treatments and therefore a lower 
chance of becoming pregnant when compared to a woman of the same age with 
normal AMH and or Inhibin B and FSH levels for her age. In a recent study at 
Aberdeen University, 600 sub fertile women undergoing ovulation stimulation 
(clomifene citrate) and IUI were compared to no-treatment expectant 
management in a randomised controlled trial. The results showed that the two 
fertility treatments had little or no effect on conception rates and that one in five 
of those who took clomid suffered side effects including nausea, bloating and 
abdominal pain. The study concluded that only IVF and ICSI should be offered to 
infertile couples (Bhattacharya et al., 2008, p.716-717) 
 
2.4 Biomedical female fertility measurements 
There are three generally used measures of female fertility; ovarian function, 
endometrial quality and progesterone level. These are commonly viewed as the most 
important measurements of female fertility together with checking that fallopian tubes 
are open and functional (Brosens et al., 2004, p.1689-1692).  
 
2.4.1 Ovarian function 
The ability of each ovary to mature primordial follicle into antral follicles and then 
a dominant or Graafian follicle is required to allow ovulation. Transvaginal 
diagnostic ultrasound has proven to be an accurate tool for measuring follicle 
development and ovarian function and is the accepted method of ovarian follicle 
development diagnosis. This is because transvaginal ultrasound allows imaging of 
the ovary in close proximity (3-4 mm) providing very clear images of each follicle 
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and accurate follicular volume measurement (Saxton et al., 1990, p.695-699). By 
day ten one of the antral follicles on one of the ovaries attain a diameter of at 
least 10 mm; this then becomes the Graafian follicle. The Graafian follicle grows 
at an almost linear rate of 2-3 mm per day for the next 4-5 days and at ovulation 
the Graafian follicle will have a mean diameter of 21.4 mm (range 17.4-27.0 mm) 
(Bakos et al., 1994, p.11). The optimum size of the Graafian follicle at ovulation 
has been shown to be between 16 and 18 mm with larger and smaller sizes 
reducing the likelihood of pregnancy (Ghosh et al., 2003, p.328-335). In addition 
the number of follicles present on each ovary was shown in the same study to not 
be associated with pregnancy outcome. The entire development of follicles from 
antral follicle to Graafian follicle can be observed and reliably tracked 
sonographically. This is also true for assessing the post ovulatory phase of the 
menstrual cycle starting with the disappearance of the Graafian cystic structure 
in the ovary and subsequent development of the highly vascular corpus luteum 
and presence of follicular fluid in the Pouch of Douglas. Proliferation of luteinised 
granulosa cells give rise to the corpus luteum which appears sonographically as a 
hypoechogenic structure at the site of the Graafian follicle (Bourne et al., 1996, 
p.5).  The commonly used measure of the ability for a woman at any stage in her 
reproductive life to conceive is the anterior pituitary hormone, FSH which is 
secreted initially on day one of the menstrual cycle and acts on ovarian tissue to 
stimulate follicle development. The ovary in turn responds by growing follicles 
and therefore secreting oestradiol 17 (E2) which acts as a negative feedback to 
the anterior pituitary gland, reducing FSH. Therefore the lower the FSH on cycle 
day (CD)1 or 2 the more responsive the ovaries are to follicle development.  
Levels between 2 IU/L and 10 IU/L are normal with fertility levels of a young 
healthy woman being closer to two and peri-menopausal women being 10 IU/L or 
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above; menopausal women have FSH levels of between 15 IU/L and 50 IU/L. FSH 
is measured in a serum sample taken from a venous blood draw on CD1 or 2 for 
most accurate results (Sehested et al., 2000, p.1634-1640). The follicles present 
on each ovary just prior to ovulation and the presence on one or other ovary of a 
Graafian or dominate follicle. Ovulation time varies from woman to woman and 
on cycle length and is usually measured by trans-vaginal B mode ultrasound 2-3 
days before the usual ovulation day. Research has shown the number of follicles 
> 15 and size between 15 and 23 mm appear to result in high fertilisation rates 
compared to smaller follicles (Ectors et al., 1997, p.2002-2005).  
 
2.4.2 Endometrial quality 
The state of the endometrium has already been demonstrated to be of major 
importance for successful implantation and ongoing pregnancy (Glissant et al., 
1985, p.786) and many previous workers have also reported significant correlations 
between endometrial thickness and pregnancy rate (Fleischer et al., 1991, p.93-95). 
It is oestradiol secreted by the developing follicles on each ovary that not only 
moderates FSH, but also acts to proliferate the endometrium thereby creating a 
nourished and highly vascular tissue bed for the embryo at blastocyst development 
level to implant into. Several investigators have evaluated the endometrial 
membrane to study whether or not there is an optimal endometrial thickness or 
texture (Fleischer et al., 1984, p.341-346, Rabinowitz, 1986, p.824-828, Thickman et 
al., 1986, p.197-201). These studies were in general agreement that endometrial 
thickness of less that 7 mm at mid luteal phase (implantation time) and/or poor 
uterine blood supply (PS  < 30 cm/s or PI > 3.0) or hypoechoic texture on 
ultrasound examination would be sufficient to cause implantation failures. The 
sonographic appearance of the endometrium changes throughout the menstrual 
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cycle. In the menses phase, the endometrium is a thin broken isoechoic interface. 
In the follicular phase, it thickens and becomes isoechoic at between 5-13 mm. 
Between 1-6 days before ovulation there is a change from one to three echogenic 
lines and an increasing hypoechogenic texture between the lines with a thickness 
between 12-13 mm with the uterus enlarging because of the proliferation of the 
endometrial compared to a menstrual uterus. Post ovulation, the endometrial 
thickness increases to a range between 10-16 mm (Bakos et al., 1993, p.799-806) 
for normally fertile women. If the endometrium is of insufficient thickness or 
quality then, even if conception takes place, implantation will not be successful. 
Therefore, prognostic values predictive of embryo implantation and ongoing 
pregnancy include endometrial thickness between 15 and 18 mm measured with 
trans-vaginal ultrasound on cycle day 21 of a normal 28 day cycle (Tomlinson et al., 
1996, p.1892-1896). This is because there is a direct correlation between 
progesterone levels at 7-9 days post ovulation and the dilation and increased flow 
of blood in the endometrial spiral arteries. This has the effect producing an 
endometrial tissue bed which is highly vascular and because ultrasound wave 
reflection and refraction is lower in fluids and higher in tissue then the images 
become more echogenic with increasing spiral artery dilation and blood flow. 
Therefore endometrial quality at 7-9 days post ovulation can be observed and 
categorised based on the level of echogenicy seen in the ultrasound images. A non-
active endometrium at 7-9 days post ovulation is pathological and has the 
appearance on ultrasound of an echo poor texture because the spiral arteries are 
non dilated restricting blood flow in the spiral arteries and obstructing embryo 
implantation. This is termed a luteal phase defect and is often accompanied with 
intramenstrual bleeding (Jones Jr, 2008, p.e5-e7). Luteal phase defects are usually 
not related to the follicular phase of the menstrual cycle. It is possible to have a 
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perfectly normal folliculogenesis with several antral follicles on each ovary and a 
large (20-25 mm) graafian follicle which together produce sufficient oestradiol to 
develop and thicken the endometrium sufficiently but either a non-luteinised 
graafian follicle or a dysfunctional corpus luteum results in reduced progesterone 
secretion and therefore a defective endometrium. Endometrial biopsy’s taken at 7-
9 days post ovulation in women with poor endometrial quality show either out of 
phase endometrial cell development or abnormal cell structure on histology which 
are unable to respond to progesterone stimulation (Peter A.W. Rogers, 2003, 
p.412-419). 
 
2.4.3 Progesterone levels  
This hormone is secreted by the corpus luteum immediately post ovulation and 
plays an important role in endometrial receptivity by maintaining the prolific 
endometrium until a pregnancy establishes itself and the placenta can produce 
sufficient progesterone to take over maintenance of a healthy endometrium 
essential for a viable ongoing pregnancy. Progesterone produced during the normal 
menstrual cycle influences endometrial sub epithelial vascularlisation causing 
dilation of the spiral arteries in the post-ovulatory phase of the cycle. This dilation 
may be related to the development of oedema appearing in the endometrial 
stroma at the time of implantation which also increases echogenic texture 
appearance on ultrasound examination (Peek et al., 1992, p.906-911). During 
folliculogenesis formation of new small blood vessels occurs within the ovary. A 
capillary plexus is formed in the theca layer during follicular development. At 
ovulation, capillaries of the thecal layer proliferate into the avascular granulosa 
layer as shown by (David, 1943, p.251-291) leading to a functional corpus luteum 
immediately post ovulation. The quality of the corpus luteum and maintenance of 
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the endometrium has traditionally been measured by a CD21 serum progesterone 
and corpus luteum size and blood supply (Vasconcelos et al., 2001, p.307-314) with 
peak follicular systolic velocity has been shown to be the most sensitive indicator of 
the corpus luteum angiogenic process and therefore progesterone secreting 
potential (Campbell et al., 1993, p.433). During stimulated IVF cycles a significant 
relationship between peak follicular systolic velocity immediately before 
ultrasound-guided ovum pick-up and subsequent formation of good quality pre-
implantation embryos and endometrium has been demonstrated (Nargund et al., 
1996, p.109-113). These parameters are measured by Power Doppler (PD) 
ultrasound on the same cycle day serum progesterone levels are measured. 
Doppler ultrasound identifies the presence of blood flow within vessels and the 
direction of flow. With PD replacing direction of flow with velocity of flow the more 
sensitive the PD electronics and the more sophisticated the software in the 
machine the more sensitive the PD measurements. Therefore more of the small 
capillaries are picked up and added into the overall PD measurements. Doppler 
assessment of blood flow and velocity are reported as pulsatility index (PI), a 
measure of blood flow velocity (PI = systolic velocity - diastolic velocity/mean 
velocity (S - D / A) and resistance index (RI), a measure of the level of attenuation in 
blood flow. Resistance Index (RI = systolic velocity - diastolic velocity/systolic 
velocity (S-D/S)).  The normal acceptable uterine artery indices for implantation 
and ongoing pregnancy are PI > 3.0 and RI < 1.0 was researched and tabulated by 
(Steer et al., 1992, p.372-376). Although Doppler assessment of the uterine arteries 
has been used before to assess endometrial flow there are two issues to consider. 
Firstly, consistency of measurements with repeatability is very poor with uterine 
artery Doppler measurements. Secondly, Doppler uterine artery measurement only 
assesses the velocity and resistance to flow within the input vessels to the uterus. 
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There is no assessment of the endometrial capillary bed or the sub endometrial 
basal interface and layer Raine-Fenning (2003). The 3D PDA methods are a much 
more appropriate method of assessing sub endometrial blood flow measuring the 
entire capillary bed within the shell contour and with proven repeatability and 
interoperator repeatability (Raine-Fenning, 2003, p.283-291). Therefore 3D PDA 
will be adopted as the ultrasound measurement used in this study. 
 
2.4.4 Fallopian tube function  
For a woman to achieve a natural pregnancy and therefore be fertile one or both of 
her fallopian tubes must be open and functional. This provides the anatomical 
pathway for sperm to move from the vagina through the cervical canal into the 
uterus and then travel into the fallopian tubes where fertilisation occurs when the 
sperm meet the occyte collected by the fimbria at the distal end of the fallopian 
tubes.  Assessing fallopian tube function is part of standard fertility diagnosis 
(Evers, 2002, p.151-159).   
2.5 Embryo implantation 
Any successful implantation requires the development of a receptive endometrium able 
to respond to the signals from the blastocyst at 7-9 days post ovulation at arrival in the 
uterine cavity. The receptive state develops under the influence of steroid hormones as 
well as paracrine signals from the embryo according to Sharkey & Smith (2000). The 
endometrium is a specialised hormonally regulated tissue type that is non-adhesive for 
embryos throughout most of the menstrual cycle in humans and other primates. 
Therefore, endometrial receptivity is a self limited period in which the endometrial 
epithelium (EE) acquires a functional and transient ovarian steroid-dependent status. The 
luminal EE acquires the ability to adhere to the developing human blastocyst (receptivity) 
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during this period, mainly due to the presence of progesterone after the appropriate 17 
beta oestradiol (E2) priming in the follicular phase of the menstrual cycle (Simon et al., 
1997, p.2-3). The process of embryonic implantation requires the participation of both 
embryo and endometrium culminating with the apposition and attachment of the 
blastocyst to the maternal endometrium during the period called the window of 
implantation, and invasion of the trophoblast in the late secretory phase.  The presence 
of a receptive uterus has been found to be one of the major factors in determining 
conception Implantation and depends on the development of normal endometrium, 
which allows placentation and the maintenance of gestation and placental separation 
after delivery (Friedler et al., 1996, p.323-335) . A mathematical analysis put forward by 
Friedler et al (1996) estimated a relative contribution of uterine receptivity to conception 
as being 31-64%. This estimate agrees with the coefficient of uterine receptivity, 
determined as 0.43 based on a previously designed statistical model by Fishel et al.(1985).  
 
There are currently thought to be several causes of poor endometrial receptivity and 
given this is an area of recent and ongoing research it is highly likely that many more 
causes are yet to be discovered. Endometrial receptivity defects are generally described 
as luteal phase defects (LPD) and have been long associated with low oestrogen levels 
(Sharkey & Smith, 2003, p.289-307). This is due to the presence of circulating oestrogen 
(oestradiol or E2) produced by the granulosa cells of the developing antral follicles which 
start the proliferation of the endometrium shortly post menses. If sufficient E2 is produced 
and reaches the endometrial tissue then rapid development and thickening of the 
endometrium takes place during ovulation leading to full endometrium development and 
receptivity. It is then progesterone from the corpus luteum which maintains the 
endometrium in a receptive state for another 7-9 days.  If the endometrial proliferation 
slows down or arrests this can be either caused by reduced E2 production from the antral 
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follicles or obstructed blood flow into the endometrial capillary bed reducing the E2 
effects on the endometrial tissue. More recent studies into embryo implantation failure 
have also identified deficiency in particular types of immune system natural killer (NK) 
cells (particularly, CD56+ cells ) compared to healthy in-phase endometrium which is 
suggestive of delayed endometrial development in women with LPD (Tuckerman et al., 
2004, p.196-205). It is without doubt going to be the case that some percentage of 
patients in this study will suffer from this pathological cause of implantation failure. It is 
outside the scope of this particular study to evaluate this aspect of poor endometrial 
receptivity and the effects of CHM treatment, but never-the-less one which justifies a 
separate CHM effects study in the future. 
 
2.5.1 Immune system response and endometrial receptivity 
Changes in the endometrial immunological response can also have a negative 
effect on embryo implantation. A study in 2001 found that peripheral blood NK 
cells in women with unexplained infertility have a higher proportion of activated 
NK cells in vivo (Ntrivalas et al., 2001, p.855-861). This work was further developed 
in a study carried out in Australia by Inagaki et al.(2003), which analysed NK 
cytokine concentrations and matrix metalloproteinase activities in fluid collected 
from uterine irrigation of recurrent failed IVF patients during their luteal phase.  
The researchers compared to a control group of women with proven fertility and 
found that in the recurrent implantation failure group an altered pattern of intra-
uterine cytokine concentration and metalloproteinase activity was present when 
compared to the control group of normal women  However, the role of NK cells, 
interleukin (IL)-12, and IL-18 in repeated implantation failure after IVF is unclear 
and requires further exploration according to a more recent study (Ledee-Bataille 
et al., 2004, p.59-65).  A prospective observational study of 138 randomised 
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women who underwent IVF treatments carried out at the Lister Fertility Clinic, 
London UK in 2004 showed that a significant increase in the count of activated NK 
cells (CD56dim, CD16+ and CD69+) in peripheral blood is associated with a reduced 
rate of embryo implantation in IVF treatment. Also women with high CD56dim, 
CD16+ and CD69+ peripheral blood NK cell absolute count who were able to 
achieve a pregnancy had a significantly higher miscarriage rate (Thum et al., 
2004, p.2395-2400).  Immunological assessment of women with infertility is now 
carried out at specialist fertility clinics and if raised NK cells are found patients are 
treated with systemic immune modulating medicines and inflammation reducing 
steroids. Immune response factors are discussed here only for completeness; 
they are only relevant to this study in that they have been demonstrated to be 
one cause of implantation failure and it would be remiss not to recognise this fact 
as background to the subject of endometrial receptivity in Toto. 
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2.5.2 Infection and endometrial receptivity 
It has also been recently discovered that the endometrial cavity is frequently 
invaded by microorganisms, and it is likely that undetectable levels of subclinical 
infection or inflammation may also play a role in implantation failure (Romero et 
al., 2004, p.799-804) .  At this time understanding of the effects of sub clinical 
inflammation or infection is too limited to be included in this thesis. Of course, 
clinically detectable uterine and tubal infection or inflammation is well 
understood as a cause of infertility and because this level can effectively be 
screened for, diagnosed and treated. The participants in this study all had been 
previously screened for the presence of pelvic infection as part of their basic 
infertility diagnosis elsewhere. By the time participants become diagnosed as 
suffering unexplained infertility they usually have had infection causes ruled out, 
however “sub clinical” (undetectable) infection inflammation may well still be 
present and as such could be an undiagnosed factor in poor endometrial 
receptivity which had not been identified in participants previous to this study. 
 
2.5.3 Assessment of endometrial receptivity 
Electron microscopy provides the best scientific way to evaluate the cell ultra 
structure and a detailed description of the cyclical changes in uterine glandular 
cell organelles during the secretory phase of the menstrual cycle (Armstrong et 
al., 1973, p.446-460). The structure of the receptive endometrium was 
researched in normal women in 1996 and found that the receptive endometrium 
exists from day 16 onwards, culminating at days 17 to 20 and disappearing 
abruptly around day 22 (Dockery et al., 1996, p.2251-2256) which is helpful in 
determining the right time of the menstrual cycle in our sample groups to collect 
data. 
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However, the exact role of endometrial cell molecular morphological changes still 
remains unclear at this point therefore cytological changes in the endometrium 
would not be a reliable method to measure the effects of treatment therapy on 
endometrial receptivity in our study. The work of Armstrong et al. (1973) and 
Dockery et al. (1996) was helpful and does give a clear definition of when in the 
menstrual cycle measurements relating to endometrial receptivity should be 
made, which is 7-9 days post ovulation. This is because the journey of a fertilised 
occyte (zygote, morula, blastocyst and then embryo) takes 7-9 days to travel from 
the place of fertilisation (isthmus of a fallopian tube) to the endometrium at 
which time the embryo attempts to implant. Factors which affect the preparation 
of this endometrium are oestrogen, correct endometrial cell staging and 
progesterone. For this study the relevance of this data is that the post ovulation 
timing for the 3D PDA scan and progesterone blood draw would be 7-9 days post 
ovulation (or CD21 on a 28 day cycle). 
 
2.5.4 Ultrasound imaging assessment of endometrial receptivity 
Diagnostic ultrasound imaging techniques for gynaecology were developed in the 
1970’s to assess many important clinical factors associated with infertility and to 
diagnose and measure the effectiveness of many gynaecological treatments in 
general. These included high resolution images obtained from close ovarian and 
uterine proximity via transvaginal (TV) scanning, Doppler measurements of ovarian 
and uterine blood vessel flow volume, velocity and resistance, endometrial 
thickness and echo texture and corpus luteum blood supply level. 
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Because of the wide range of gynaecology physiology and pathology transvaginal 
ultrasound has become the main “workhorse” of infertility and early pregnancy 
diagnosis and treatment monitoring today. In 1998 Kretztechnik AG, an Austrian 
medical imaging company, made a major breakthrough in gynaecology ultrasound 
technology and marketed the first three dimensional (3D) ultrasound machine 
capable of imaging entire organ structures, rather than displaying individual image 
slices through an organ structure (2D).  More importantly for infertility applications 
the Kretztechnik machine allowed for the first time the entire blood vessel 
structure contained inside the ovaries and the uterus to be studied and vascular 
flow parameters to be measured as a single set of observer independent 
repeatable indices. The method of uterine blood flow assessment and the 
procedure for taking reliable, repeatable measurements using 3D Doppler 
ultrasound was defined by (Raine-Fenning et al., 2004, p.330-338) and were the 
methods used in this study. Previous studies before the advent of 3D power 
Doppler scanning examining uterine perfusion during the menstrual cycle used 2D 
power Doppler analysis of the uterine vessels (Steer et al., 1990, p.391-395, Bourne 
et al., 1996, p.5). These two studies focused on assessing blood flow in the uterine 
arteries as apposed to the endometrial flow or sub endometrial flow.  
Subsequently, evidence became available in the form of clinical studies that 
measuring the blood flow in the sub endometrial capillaries using 2D power 
Doppler ultrasound (Sladkevicius, 1993, p.199-208) and provided improved 
diagnostic value . This has been disputed by (Raine-Fenning et al., 2004, p.330-338) 
highlighting differential blood flow with greater impedance to flow in spiral arteries 
located in the posterior aspect of the uterus based on work by (Hsieh, 2000, p.192-
196). The basis of Raine-Fenning’s argument is the fact that accurate and 
repeatable measurement of blood flow in any vessel requires careful angle 
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correction and accusation of a well defined Doppler wave form which is only 
suitable for large vessels and not the small spiral vessels within the sub 
endometrium also supported by (Nelson & Pretorius, 1988, p.439-447). Power 
Doppler is a far superior method of assessing spiral artery flow and velocity within 
the sub endometrium because of its greater sensitivity to small vessels and low 
velocity flow which is angle independent compared to gated Doppler 
measurements (Rubin et al., 1994, p.853-856). With power Doppler, vessels are 
assessed by measuring the power in the Doppler signal rather than the mean 
frequency shift. By combining 3D ultrasound with PD it is then possible to assess 
every slice of the 3D data acquisition with the PD flow information therefore 
providing a complete accumulated measurement of all the flow within the sub 
endometrium (Downey et al., 2000, p.559-571). This new system of ultrasound 
assessment of a blood vessel matrix is then termed 3D power Doppler angiography 
or 3D PDA for short and although state of the art and available commercially since 
1998 3D PDA has only been used recently to predict the response to IVF ovarian 
stimulation and link the 3D PDA indices gathered to pregnancy outcome (Schild et 
al., 2000, p.89-94). Therefore the ability to image an entire endometrial structure 
and layers and measure the vascularity within the sub endometrial area of the 
uterus provides the best available, accurate and repeatable ultrasound method of 
measuring endometrial receptivity (Raine-Fenning, 2003, p.633-639). For all the 
reasons discussed above sub endometrial 3D PDA was the ultrasound 
measurement method selected for this study. 
 
2.5.5 Measuring endometrial receptivity using 3D Power Doppler Angiography  
It has been established by numerous previous workers that uterine artery 
heamodynamics  (Goswamy et al., 1988, p.955-959, Steer et al., 1990, p.391-395) 
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and endometrial thickness (Steer et al., 1992, p.372-376) correlate with pregnancy 
rates.  Therefore endometrial thickness and 3D PDA sub endometrial vascular flow 
will be used to measure the impact of our proposed treatment and correlate with 
the pregnancy rates. In 1999 a co-located group of researchers from Yale University 
School of Medicine and Valencia School of Medicine conducted a study to assess 
the effect endometrial volume may have on endometrial receptivity.  The 
researchers used 3D ultrasound at embryo transfer to measure the endometrial 
volume of 72 women undergoing IVF cycles and classified the group according to 
endometrial volume (group A = < 2 ml and group B = 2-4 ml) and showed that 
implantation and pregnancy rates were significantly lower (P < 0.05) in group A 
compared to group B (Raga et al., 1999, p.2851-2854). Three-dimensional power 
Doppler angiography (3D-PDA) takes the pure 3D volume assessment of the 
endometrium a stage further and for the first time facilitates the examination and 
categorisation of normal and abnormal endometrial and sub endometrial 
vascularity particularly spiral artery endometrial blood flow (Schild et al., 2000, 
p.89-94, Schild et al., 2001, p.361-366, Raine-Fenning et al., 2004, p.330-338). 
Advances in 3D-PDA software analysis tools such as virtual organ computer –aided 
analysis and shell-imaging (VOCAL from GE Medical System) now allows the exact 
quantification of the power Doppler signal within the entire endometrium or sub 
endometrial areas allowing vascular indices to be reliably measured and compared 
for total VI, FI and VFI within the selected area of examination. Raine-Fenning et al 
(2004), found that both the endometrial and sub endometrial VI and VFI increased 
during the proliferative phase of the normal menstrual cycle peaking approx 3 days 
prior to ovulation before decreasing to a nadir 5 days post ovulation and then 
gradually increasing during the transition from early to mid secretory phase (Raine-
Fenning et al., 2004, p.2605-2614).  The FI showed a similar pattern but with a 
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longer nadir post ovulation, they also showed that the VFI and FI were significantly 
lower in women aged > 31 years and significantly higher in parous women. Three 
dimensional PDA has also been used to investigate endometrial morphology and 
sub endometrial perfusion on the day of embryo transfer showing that women 
who became pregnant were characterised by a significantly lower resistance index 
obtained from sub endometrial vessels and significantly higher FI measured by 3D-
PDA (Kupesic et al., 2001, p.125-134). One of the first 3D-PDA clinical studies 
published relating to fertility was in Human Reproduction in 2004 investigating 
endometrial and sub endometrial perfusion in women with unexplained fertility. 
The study used 3D-PDA and shell imaging analysed with the VOCAL histological 3D 
volume software tool to compare endometrial and sub endometrial vascularity on 
alternate days throughout the menstrual cycle in a normally fertile women control 
group with an unexplained infertility group. The researchers found no difference in 
endometrial thickness or volume between the groups or in the plasma 
concentrations of oestradiol or progesterone. However there were significant 
reductions in both endometrial and sub endometrial vascularity in the unexplained 
infertility group (Raine-Fenning et al., 2004, p.2605-2614).  A study by (Ng et al., 
2004, p.924-931) found that endometrial and sub-endometrial Doppler flow indices 
(VI, FI and VFI) were significantly different between moderate and excessive IVF 
responders indicating a clear link between ovarian activity, hormone levels, sub 
endometrial blood flow and 3D-PDA index measurements. In 2005, a breakthrough 
paper was published in the Journal of Reference & Clinical Assisted Reproduction 
(Raine-Fenning & Fleischer, 2005, p.10) which detailed the clinical applications of 
3D transvaginal ultrasound in reproductive medicine based on evidence based 
research. They described the methods to be employed when using 3D-PDA 
ultrasound in the assessment of uterine abnormalities, intrauterine pathology, 
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tubal patency, polycystic ovaries, ovarian follicular monitoring and endometrial 
receptivity.  Related work carried out at the University of Hong Kong to determine 
the factors affecting endometrial and sub-endometrial blood flow measured with 
3D-PDA found that endometrial blood flow in IVF treatments cycles was negatively 
affected by serum E2 concentration and not all affected by age, smoking habits, 
types of infertility, parity, causes of infertility (Ng et al., 2006, p.1062-1069). Three 
dimensional PDA was also used in a follow on study by the same team of 
researchers to investigate endometrial thickness, endometrial pattern, uterine 
artery Doppler flow indices, and endometrial volume, VI, FI and VFI of the 
endometrial and sub endometrial regions of the uterus. This study demonstrated 
that 28% of those patients achieving an IVF pregnancy subsequently miscarried and 
that those who continued their pregnancy to term had a significantly higher 
endometrial VI and FI and sub-endometrial VI, FI and VFI, when compared to those 
who miscarried (Ng et al., 2007, p.1134-1141). Overall the study showed that both 
endometrial and sub-endometrial vascularity was significantly higher in pregnant 
patients with live birth than those who suffered a miscarriage. However an 
important finding was that only endometrial VI was significantly associated with 
live birth rate (P = 0.034).  
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2.6 Traditional Chinese Medicine infertility treatment 
Whilst conventional biomedicine has developed these diagnostic and treatment 
techniques over the last 50 years, other more traditional approaches to fertility treatment 
have been widely and successfully used in the east for thousands of years. Since the 
Western Han Dynasty, 206 BC.- 24 AD Chinese women have been using traditional 
Chinese Medicine (TCM) to effectively treat female infertility. To date, there has been 
little or no exchange of learning or indeed integration of these traditional approaches 
with Western conventional medicine. The dilemma is integrating two divergent 
philosophies, metaphysics, the foundation philosophy of all Western conventional 
medicine, and epistemology, the foundation philosophy of all eastern holistic medicine is 
at the center of this separation. Historically, CM represents a heterogeneous array of 
ideas and practices developed over the past 3000 years (Unschuld, 1985, p.34) and a 
growing issue between TCM and conventional medicine  is whether or how to integrate 
CM theory with conventional medicine understandings (Unschuld, 1992, p.44).  
 
2.6.1 Integration of conventional and traditional medicine 
Over the past century, CM has been exposed to increasing influence from outside 
forces, such as Marxism and Western science (Unschuld, 1992, p.44). Given the 
advancement and hegemony of biomedical science, many indigenous medical 
systems including CM have suffered disintegration and to some extent dismantling 
of their philosophical underpinnings (Alderte, 1996, p.377-385). The dismantling is 
a result of conventional medicine inquiry into the tools of practice employed by the 
systems under investigation (Fruehauf, 1999, p.6). From a biomedical perspective 
TCM presents itself as a series of potentially useful and exploitable technologies 
with tangible assets and practices such as CHM and acupuncture each to be 
evaluated through well conducted evidence based RCT methodology.  The purpose 
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of such inspection is to expand the realm of biomedical practice by including 
specific herbal medicines or practices proven to be efficacious and safe through 
controlled scientific experiment (Rees & Weil, 2001, p.119-120).  There are now 92 
medical schools in China teaching; Integrated Western conventional medicine 
and Chinese Medicine (IWCM) and to date over 100,000 physicians in China have 
received this training and are engaged in practice, teaching and research and 
there are 15 IWCM journals published in China today (Hao Xu, 2008, p.5-7). 
 
2.6.2 Infertility treatment using Chinese medicine 
There are two levels of infertility treatment using CM. The first level uses herbal 
medicines which can enhance a woman's ability to conceive naturally and we now 
know that one of the major effects of CM appears to be on ovarian activity and 
endometrial quality (Wing & Sedlmeier, 2006, p.26-32).  Using these natural 
medicines can increase not only the number of available oocytes which mature and 
are then available for fertilisation, but also the quality of the maturing oocytes. 
CHM treatment combined with basal body temperature charting (BBT), ultrasound 
follicle tracking and hormone level tests to determine optimum time in the cycle 
for conception can dramatically increase a woman's chances of conception and 
successful implantation. The second level is natural in-vitro fertilisation following 
the IWCM approach to care and now used commonly in China. In this case a 
woman matures her oocytes and Graafian follicle naturally and just before 
ovulation a single mature oocyte is extracted using a minimally invasive needle 
follicle aspiration. In the laboratory, the extracted oocyte is married with her 
partners (or donated) sperm and the resulting embryo is replaced into the uterus 3-
5 days later once the fertilised oocyte has began developing normally. CHM is 
administered throughout the natural cycle IVF treatment to maintain the quality of 
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the endometrium and to minimise the chance of early miscarriage. There are many 
advantages to this approach: CHM is a complete traditional medical health care 
system and can be used with or without the integration of conventional medicine 
fertility treatment. The integration of conventional medicine with TCM began in 
the Orient less than a century ago. This is achieved by combining Western and 
eastern diagnostic techniques to arrive at a holistic diagnosis which is then 
treating with the appropriate combination of conventional medicine drug 
therapy, acupuncture, herbal medicines and dietary therapy and where 
appropriate supplemented with modern assisted conception procedures (Hao Xu, 
2008, p.3-7). When applied to infertility, this approach is best termed "Integrated 
Fertility Treatment" (IFT) and could provide an improvement in success rates 
available today with just conventional biomedicine treatment. However, for IFT 
to be seriously considered by the conventional biomedicine fertility community 
evidence based studies must be undertaken and published. This study is designed 
to contribute to the evidence base of research on CHM infertility treatment 
effectiveness and particularly in this case related to endometrial receptivity to 
embryo implantation. 
 
2.7 Pharmacological effects and chemical composition of CHM  
The chemical composition of each herbal medicinal used in the formulas used in this 
study is well documented, as is the pharmacological effects. Each herbal medicinal has 
been biochemically analysed and has an internationally agreed monograph and published 
in several CHM pharmacopeia texts such as “Chinese Medical Herbology and 
Pharmacology” (Chen, 2004). The therapeutic effects of individual medicinals in 
biochemical terms can be used to link treatment outcomes to the physiological changes 
during the treatment process. However what has not been studied with any meaningful 
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scientific outcome is how the chemical composition and pharmacological effects of 
individual medicinals change when combined. It is the synergistic combination of 
medicinals or polypharmacy formulas combined with individual patient diagnosis that is 
widely regarded as the reason CHM is such an effective and safe medical system.  
 
2.8 CHM medicinals-drug interactions 
The term used to describe the interaction of pharmacologically active substances in the 
body is pharmacokinetics. Because pharmaceutical medicine is a recent treatment 
mechanism relative to CHM and even more recent is the combination of CHM and 
pharmaceutical medicines in the same patient since CHM was only brought to the West 
in the 1950’s. The subject of herb-drug interaction is a very recent subject, indeed only 
two substantial texts exist in the West (Chan, 2000, Jennes, 2004) the oldest written in 
2000, much more research is needed in this area. Pharmacokinetics defines the 
movement of all “foreign substances” (substances not of the human body’s biological 
origin) through the body. The substances can be of pharmaceutical drug, herbal 
medicine and food origin and they are known collectively as “xenobiotics”.  Any 
medicinal substance delivers its intended therapeutic effect firstly, by absorbsion at the 
place of first contact with the body and then is distributed within the body to the 
intended organ or system. The effects of the medicinals are diminished over time by the 
process of either metabolism or elimination.  Absorbsion, distribution, metabolism and 
elimination characteristics of any medicinal substance are abbreviated to, and widely 
referred to as “ADME” characteristics. 
 
2.9 CHM medicinals toxicity 
CHM are of course toxic as are all internally absorbed substances in sufficient amounts 
including foods and food supplements. Toxicity is divided into three categories: heavy 
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toxicity, minor toxicity and no toxicity. According to Chinese medicinal pharmacology, 
serious toxic effects are coma, nausea, numbness in the mouth and in the limbs and 
Medicinals with minor toxicity if used in high dosages can cause mild breathing 
difficulties, abnormal heartbeat and dizziness. These effects are most commonly 
associated with two causes, hepatoxicity (liver) and nephrotoxicity (kidneys). The third 
major area of toxicity concern is fetotoxicity (in-uterus fetus). Medicinals without toxicity 
are mild in nature and in normal use very rarely have any side effects at all.  All commonly 
used CHM medicinals are safe and non-toxic when prescribed according to TCM disease 
diagnosis and pattern discrimination and with the correct dosage for the appropriate 
length of time (Chan & Critchley, 1996, p.5-12). In order to reduce the toxicity effects 
CHM pharmacies use the traditionally proven pre-processing methods, such as heating or 
infusing with various liquids. In addition the UK CHM pharmacopeia is controlled by the 
Medicines and Healthcare products Regulatory Agency (MHRA) and medicinals in the 
heavy toxicity (and many of the medicinals in the minor toxicity) category has been 
removed from the UK CHM pharmacopeia by the MHRA. This approach to control CHM 
safety will have limited effect as UK qualified and RCHM registered CHM practitioners are 
trained to a very high standard and are well qualified to manage the appropriate and safe 
use. Yet, CHM high street stores (with non UK trained and registered practitioners) 
usually do not use or adhere to the MRHA controlled pharmacopeia importing the 
medicinals used directly from China in most cases. CHM formulas contain a complex and 
synergistic mixture of compounds such as alkaloids, polysaccharides and terpenes or 
other chemicals that harmonise, modulate and modify the effects of the active 
ingredients of an individual medicinal. Therefore, toxicity analysis of isolated medicinals 
cannot be used to determine the toxicity level of an entire formula. Scientific studies on 
an isolated medicinal are often incorrectly related to the formula as a whole and 
analysing each and every variation of formulas used in everyday practice is not feasible or 
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practical. Therefore it would seem that the best way to ensure a safe and effective CHM 
service to the public is to regulate CHM practitioners in the same way conventional 
medicine practitioners are regulated, by setting standards for education and examination 
and making statutory registration mandatory, whilst allowing the CHM pharmacopeia to 
remain intact and available in full, BUT only to qualified, registered UK practitioners. 
 
2.10 CHM medicinals and endangered species 
There is always concern from patients and the general public regarding CHM and 
endangered species, tiger bone always comes to mind first, although there are many 
other endangered animal and plant species. UK qualified and registered practitioners are 
only licensed to source CHM from a small number of MHRA and RCHM approved 
pharmacies that strictly adhere to the requirements of both UK controlling bodies. 
Unfortunately, the same cannot be said for the CHM high street stored operated by 
predominantly Chinese practitioners outside the UK profession registration and control 
systems. The following is the current RCHM position on endangered species.  
“The RCHM is greatly concerned about the threat to wild animals and plants that have 
come as a result of the growth in demand for traditional medicines. We strongly condemn 
the illegal trade in endangered species and have a strict policy prohibiting the use of any 
type of endangered species by any of our Members. The RCHM uses information supplied 
by Convention on International Trade in Endangered Species (CITES), the Wildlife Liaison 
Office of the Metropolitan Police and the Department of the Environment, all of whom 
work to stop the trade in illegal substances wherever it is found” 
 (RCHM, 2008, p.RCHM poilicy on endangered species) 
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2.11 Literature review summary  
This literature review deals with implantation failure in ART and subsequent early 
pregnancy failures and the empirical positive effects of treatment with CHM.  
 It shows that there women in the 3rd and 4th decade of their lives are most likely to 
require infertility treatment and that there are 5 main causes together with occyte 
aging. It also shows that unexplained infertility is the area of least understanding and is 
most beneficial for research. The major reason for unexplained infertility understood 
today is endometrial receptivity. It also shows that complementary medicine and 
particularly CHM is promising in its ability to improve endometrial receptivity. It also 
shows that 3D-PDA ultrasound provides a scientific, proven, repeatable method of 
measuring endometrial receptivity. We propose to undertake a study to assess the 
effects of CHM on human endometrial receptivity using 3D-PDA sub endometrial 
vascularity assessment together with serum FSH and progesterone hormone 
concentrations as the measurement system. Our understanding is that the effects of 
CHM on endometrial receptivity have never before been studied before. We therefore 
plan to study the effects of CHM on both a normal healthy group of women and a failed 
IVF group of women.  
 
The research question for the reference group is “to what extent does CHM affect the 
endometrial receptivity of normal healthy women” and the research question for the 
treatment group is “to what extend does CHM affect the endometrial receptivity of 
women with unexplained infertility who fail IVF treatment” 
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CHAPTER III  
TREATMENT GROUP METHODOLOGY 
The aims of this thesis were two fold: to investigate the effectiveness of CHM in a group 
of failed IVF patients (Treatment group) and to assess the effects of CHM on the 
endometrial receptivity of normal healthy volunteers (Reference group). The research 
was therefore conducted in two parallel stages as follows. 
 
3.1 Investigation method 
The method of investigation used for the treatment group of this study was determined 
after evaluating several different approaches which would be appropriate to answer the 
research question posed. Each method was defined and the advantages and 
disadvantages evaluated to determine the most suitable method for this study. Most 
previous studies into the effectiveness of CHM have not used prospective, longitudinal, 
clinical intervention studies. Instead most have used retrospective, case study series 
analysis. There are good reasons for the shortage of evidence based TCM research 
studies to date (discussed below) and these reasons also affect the design and 
methodology used in this study and therefore are important to discuss. 
 
3.2 Complexities specific to studies using Chinese herbal medicine 
There were complex issues to be overcome in the development of this study which are 
common to any study of CHM.  The most robust type of research study to investigate the 
effectiveness of any type of medicine is a randomised control trial (RCT).  The RCT is an 
experimental design to identify causation; its strengths to minimise bias are: 
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randomisation, the presence of a control group and blinding of the participants and the 
clinicians (Hannan, 2008, p.211-217).  
 
This is just as true for CHM as conventional pharmaceutical medicines; however, to carry 
out an RCT on CHM would require two conditions to be met. Firstly, patients would need 
to agree to being randomised into receiving treatment or placebo and secondly, ethics 
approval would need to be granted to carry out such an RCT study using CHM. After 
surveying a small group (n = 10) of failed IVF patients attending the WHNP for infertility 
treatment and also consulting the central office for research ethics (COREC), it became 
clear that neither of these two conditions could be reasonably be expected to be met and 
so an alternative approach to achieving the aims and objectives of this study had to be 
found.  In addition, according to standard TCM diagnosis methods different patients with 
the same disease are given a different treatment this means in practice that the herbal 
medicine formula used to treat each patient would be constructed with a range of 
medicinal substances and doses individualised to each patient.  Although not negating 
the use of an RCT this means the individual medicinal herbal substances cannot be 
evaluated for effectiveness only the treatment effectiveness overall can be evaluated.  
Therefore the standard prospective, blinded RCT study could not be applied to the 
treatment group and investigating which individual medicinal substances were 
responsible for any effects was not possible. 
 
3.3 Ethics considerations 
Even if ethical approval could have been achieved for an RCT with the failed IVF patient 
treatment group the author considers it unethical to withhold treatment from failed IVF 
patients in any case. Most of these patients are in the 35-45 year old age range, have 
usually exhausted all conventional medicine fertility treatment options and CHM 
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treatment is their last hope of achieving a biological pregnancy with their own eggs. In 
addition the group of 10 patients on the waiting list when asked if they would be open to 
participating in a placebo RCT all said they would decline to participate in such a study 
should it be offered to them. After consulting with COREC and the local ethics research 
ethics committees (LREC) it was decided by that NHS ethical approval was not required as 
the patients were private non-NHS patients. LREC advised that University of Portsmouth 
ethics committee approval was needed which was duly obtained (Appendix A). 
 
3.4 TCM individualised treatment background 
The practice of Chinese medicine has a long history dating back almost 5000 years. It was 
influenced by the philosophy of many different times and dynasties with Confucianism 
and Taoism having a significant effect on its definition. Already in the third and second 
centuries BC, medicine was based on the laws of nature, in the first century BC, the Huang 
di Nei Jing (The book of the Yellow Emperor) was written. It was one of the most 
important classics in Chinese medicine, in which the laws of nature were described for the 
first time. These are still valid today and during the cultural revolution in 1949 a 
government sponsored, standardised form of Chinese medicine was defined called TCM 
(Unschuld, 1985, p.34). It is this structured, logical form which allowed standardised 
teaching across china with the ensuring national standards of care (SOC) and TCM degree 
courses taught to a standardised syllabus. This is the form of Chinese medicine now most 
commonly taught in the UK and USA providing TCM medical degree qualified clinicians 
registered and licensed by their associated professional bodies (the RCHM and the BAcC) 
resulting in tightly regulated, high quality practice ensuring consistent standards of 
patient care in the UK. At the heart of the TCM approach to medicine is individual 
diagnosis and personalised treatment. The same disease in different people would have 
different treatment as unlike conventional medicine the whole person is treated not just 
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the disease. This means that each patient is diagnosed individually and receives a 
different herbal medicine formula (a polypharmacy collection of herbal medicinals) 
depending on their disease diagnosis and pattern discrimination. Standardising the dose 
and herbal medicinals used within the treatment group would limit the effectiveness and 
not conform to the accepted SOC used in the TCM system and therefore would not only 
reduce the efficacy of treatment but would be considered as unethical by TCM 
academics. Disease diagnosis and pattern discrimination is made only after questioning, 
assessing and examining the whole person as treatment can only be optimal if the 
treatment plan addresses individual disharmonies, excesses and deficiencies. Only then 
can a treatment plan and treatment prescription be constructed for each patient.  In the 
case of gynaecological conditions, TCM treatment is usually delivered via a combined 
formula of 10-20 medicinal substances. This formula is often administered on a cyclical 
basis, corresponding to each phase of the menstrual cycle and developed to address the 
individual patients disharmony observed at the physical, mental and emotional level. The 
“patient specific” customisation of the formula consists of three steps, selecting the most 
appropriate classical base formula for the individual pattern discrimination and treatment 
principle, adding and deleting medicinal substances according to the patient’s individual 
diagnosis and pattern discrimination and then choosing the correct dose of each 
medicinal substance. Liver and renal function blood tests are routinely carried out when 
previous medical history or current symptoms indicate abnormal liver or renal function 
before the formula is prescribed and regularly during treatment to ensure that no 
underlying liver or kidney weakness exists that could be adversely affected by the herbal 
medicines prescribed. Conversely in conventional medicine the same disease in different 
patients is treated with the same medicine and moreover usually only one drug is 
prescribed usually in the same doses making comparison of the effectiveness of the 
treatment in a group of patients relatively straightforward. In a conventional medicine 
  48 
 
study, one would measure the parameters related to the disease before administering 
the medicine, administer the medicine, measure the same parameters after administering 
the medicine and analyse the results. It is then possible to prove that drug (A) treats 
disease (Y) with a success factor of (X). Usually a control group is also added and the 
combined participants are randomly given placebo or treatment and the same 
parameters are measured in both the placebo and the treatment group. This is of course 
the basis of all modern Randomised Controlled clinical Trials (RCT’s) and ideally one would 
use an RCT to evaluate the effectiveness of CHM.  If one applies RCT research to CHM 
prescribed in the traditional way (an individualised combination of herbal medicines) one 
would only be able to prove that CHM treats disease (Y) with a success factor of (X), not 
which medicinal substances were responsible for the successful outcome of the 
treatment because each patient would be prescribed a specific medicinal formula 
matched to their symptoms.  Whilst a useful outcome to a clinical study about the efficacy 
and safety of CHM this approach cannot answer the question of which CHM medicinal 
substances are responsible for any positive or negative effect. Careful consideration was 
given to standardising the CHM formulas so that all patients in the study (treatment 
group or reference group) received the same medicine formula. This would put the study 
on an equal footing to conventional pharmaceutical trials and has the advantage of 
proving if a particular standard formula is effective and to what degree it is effective. This 
approach would also have the benefit of allowing the study to be repeated elsewhere and 
setting foundations for further studies by others in the future looking into which 
medicinal substances or combination of medicinal substances were responsible for which 
therapeutic effects. The disadvantage is this is not the accepted way of treating using 
TCM and would be regarded as nonsense inside the TCM profession. 
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3.5 Study design options 
In order to answer the research questions the study was designed as a prospective, 
longitudinal, interventional clinical study using reliable, previously proven physiological 
parameters of endometrial receptivity which were measured before and after treatment 
with CHM. The nature of this study suggested the following four alternative methods of 
investigation.  
 
A) A sample group of failed IVF patients registering with the WNHP for 
TCM infertility treatment who receive normal treatment and are willing 
to allow the data obtained in the course of their treatment to be used in 
the study anonymously.  
 
B) A sample group of failed IVF patients already attending the WNHP for 
TCM infertility treatment willing to enter an RCT to receive normal 
herbal medicine or placebo as part of their treatment. 
 
C) A sample group of failed IVF volunteers recruited from the general 
population who are willing to enter an RCT for TCM infertility treatment 
as in B above. 
 
D) A sample group of failed ART patients from several TCM infertility 
treatment centres who are willing to allow the data obtained in the 
course of their normal treatment to be used in the study anonymously 
 
 
Careful consideration was given to the inherent issues with researching TCM treatment 
discussed above (section 3.2, 3.3 and 3.4). The design most applicable to this study was 
decided to be A.   
 
Option B was considered unethical as treatment would be withheld from a group of 
infertile patients and would have (even if passed by the Ethics Committee) ruled itself out 
by lack of volunteer patients in any case as proven but the survey of patients on the 
waiting list for treatment at WNHP. 
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Option C was considered difficult to achieve as approaches to three London-based 
fertility clinics revealed that the clinics are not open sharing their waiting lists and general 
advertising for volunteers deemed to expensive and beyond the scope of this study 
financially. 
 
Option D was also considered as it would have the benefit of enlarging the sample 
population but have the disadvantage that the biomedicine parameter collection model 
(particularly the use of advanced 3D Doppler ultrasound) in TCM infertility diagnosis is (as 
far as we know) unique in this country to The WNHP where the standard method of 
treating infertility is to carry out a monitored menstrual cycle measuring a range of 
biomedical parameters collected throughout the monitored cycle using ultrasound 
examinations and serum hormone levels.   
 
In conclusion then Option A, - a sample group of failed IVF patients registering with the 
WNHP for TCM infertility treatment who receive normal treatment and are willing to 
allow the data obtained in the course of their treatment to be used in the study 
anonymously appeared to be the best pragmatic route to choose. 
 
3.6 Study design 
The study design selected for the treatment group to address the above complexities and 
answer the research question “to what extent does CHM affect the endometrial 
receptivity of women who fail IVF treatment” is detailed below. 
 
3.6.1 Treatment group 
The treatment group was a prospective, longitudinal, interventional clinical 
study of a group of failed IVF patents presenting at the WNHP for treatment 
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tested before and after treatment. No change was made to their planned 
treatment at all and was recruited in the order they presented to the clinic. If 
they met the inclusion and criteria they were asked at the end of their initial 
consultation if they would be interested in participating in this research study.  
 
Each participant was given an informed consent form (see Appendix B) to read 
and sign if they wished to participate. The form made it clear that their 
treatment at the clinic would not be affected in any way at all by participating in 
the study and that the study data would be collected as part of their normal 
clinic visits and treatment plan and the data when used in the study would be 
anonymous. 
 
3.6.2 Inclusion criteria 
The treatment group inclusion criteria was; failed at least 2 cycles of IVF 
treatment in the previous two years, between 20 and 45 years of age, with a 
Body Mass Index (BMI) of 20-25, accomplished English speakers and absence of 
gynaecological pathology or abnormality (clinically already diagnosed as 
suffering from unexplained fertility).  
 
3.6.3 Exclusion criteria 
The treatment group exclusion criteria was; younger than 20 or older than 45 
years of age poor English speaker, any gynaecological pathology except 
unexplained infertility after 2 failed IVF (or ICSI) attempts and with a BMI of less 
than 20 or over 25.  
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3.6.4 Power calculation and sample size 
The sample size selected for the treatment group was based on a power 
calculation related to the degree of statistical change in endometrial parameters 
seen in our pilot study carried out in 2005 (Appendix C)  The study was powered 
to detect a significant difference in the three ultrasound endometrial outcome 
measures between pre and post treatment. 
 
1). Endometrium thickness: Pilot study results suggested a mean change over 
time of 1.9 units, with standard deviation 4.0 units. With a 5% significance level 
and 90% power, 47 subjects were required to show a significant change 
between pre and post treatment. 
 
2). Uterine Artery PSD: Pilot study results suggested a mean change over time 
of 6.6 units, with standard deviation 5.6 units. With a 5% significance level and 
90% power, 8 subjects were required to show a significant change between pre 
and post treatment. 
 
3). Uterine Artery PI: Pilot study results suggested a mean change over time of 
3.0 units, with standard deviation 6.2 units. With a 5% significance level and 
90% power, 45 subjects were required to show a significant change between 
pre and post treatment. 
 
These power calculations suggest that a sample size of 47 patients would be 
required in order to detect a significant change in all three endometrial 
receptivity related outcomes of interest. We anticipated that the treatment 
group in this study would behave in the same way as the subjects in the pilot 
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study treatment group (the same degree of changes over same treatment time). 
The pilot study showed that three menstrual cycles were sufficient to see 
statistically significant changes in the measured endometrial physiological 
parameters (Wing & Sedlmeier, 2006, p.26-32). Therefore, a treatment 
timeframe of three menstrual cycles was also adopted for this study.  
 
3.6.5 Attrition 
Since all the women in the treatment group had consented to allow their data 
to be used in the study and the fact that they were all extremely motivated to 
complete their course of treatment it was felt that drop out rate would be very 
low indeed and if there was drop out then a few more patients coming through 
the clinic would be recruited to make up the desired numbers. In reality, there 
were no drop outs in the treatment group. 
 
3.7 Interventional treatment 
It was decided not to use any standardised formulas (using the same medicinals and 
doses for every patient) giving traditional individualised CHM formulas to both the 
treatment group and the reference group in order to provide treatment conforming to 
standard TCM practice approach and ethos.  TCM is a dual diagnosis system. Firstly the 
presenting condition must be attributed to the correct classification of disease diagnosis 
(i.e endometriosis would have two correct disease diagnosis’s, pathological bleeding and 
lower abdominal pain).  The second aspect of the dual diagnosis system is pattern 
discrimination, allowing the patients pathognomonic signs and symptoms to be 
categorised according to one of the ten types of pattern discrimination listed below 
(Wexin et al., 1971). 
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1. Eight principles (internal/external, repletion/vacuity, etc) 
2. Five elements 
3. Viscera and bowel 
4. Channel and network 
5. Qi and Blood 
6. Fluid and humours 
7. Six divisions  
8. Four aspects 
9. Three burner  
10. Disease cause 
 
This is the standard TCM diagnosis system used at the WNHP and therefore all the 
patients in this study were diagnosed and treated in exactly the same way they would be 
treated attending the practice for infertility treatment as detailed below. 
Treatment group, (50 patients) received individual formulas 
based on a four phase guiding menstrual cycle basic herbal 
medicine formula which was then modified for each patient in 
the normal TCM treatment approach. The preparation was in the 
standard way for the WNHP which is granulated herbal 
medicines encapsulated into opaque 500mg vegetable capsules. 
Each patient was given between 3 -5g per day (3, 4 or 5 capsules 
twice daily). 
 
 
3.8 Adverse reactions and side effects 
Toxicity and adverse effects have always been a public and media concern related to CHM 
and there have been several reports in the media over the last 10 years of severe adverse 
reactions. Most of these are from illegal medicinals adulterated with heavy metals such as 
mercury or corticosteroid pharmaceuticals such as prednisolone supplied from 
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uncontrolled pharmacies usually directly imported from mainland China and dispensed by 
non UK registered practitioners. However, adverse reactions and side effects rarely 
happen in the UK as a result of taking CHM when prescribed by qualified practitioners; 
however in some people, as with any medicines there can still be minor side effects. The 
RCHM publishes guidelines to all members on informing patients of possible side effects 
and what action to take if they experience any adverse reactions or side effects.  In order 
to understand the toxicity aspect of the medicinals used in these study patients were 
given the RCHM approved statement on adverse reactions and asked to record any 
adverse reactions or side effects on the RCHM yellow card for recording and reporting 
adverse reactions experienced during their course of treatment (Appendix D). Any 
adverse reactions reported were tabulated in the data collection database for analysis as 
part of this study and reported to the RCHM on the yellow card recording system which is 
mandatory action for all RCHM registered practitioners. A single UK pharmacy accredited 
by the RCHM was used throughout the study (Appendix E). This ensured quality control 
and consistency of the formulas used in the study by strict adherence to good 
manufacturing practice (GMP) and ensured that no animal products, adulterated 
botanical substances or botanical species listed on the CITES endangered species list were 
used in the study (a legal requirement in the UK under the 1998 medicines act).  Also 
listed in Appendix E is the original source of each herbal medicinal used in the study. 
 
3.9 Medicinals and formulas used in the study 
The base formula used for the treatment group is detailed below, however additions and 
subtractions and doses of individual medicinals varied between patients following the 
standard TCM convention of diagnosis and pattern discrimination. 
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Menstrual Cycle Based Guiding Treatment Formulas 
500mg vegetable capsules. Dose 3 -5 BD between meals 
 
Week 1 (CD1-6) 
 
Radix salviae miltiorrhizae (dan shen) 8g 
Radix paeoniae rubrae (chi shao) 8g 
Radix paeoniae lactiflorae(bai shao) 7g 
Radix et caulis jixueteng (ji xue teng) 7g 
Follium artemisiae argyi (ai ye) 7g 
Herba leonuri heterophylli (yi mu cao) 13g 
 
Week 2 (CD7-13) 
 
Radix angelicae sinensis (dang gui) 6g 
Radix paeoniae lactiflorae(bai shao) 6g 
Radix dioscoreae oppositae (shan yao) 6g 
Sclerotium poriae cocos (fuling) 6g 
Radix rehmanniae glutinosae conquitae (shu di) 6g 
Fractus corni officinalis (shan zhu yu) 6g 
Cortex moutan radicis (mu dan pi) 7g 
Rhizoma alismatis orientalitis (ze xie) 7g 
 
 
Week 3 (CD14-20) 
 
Radix angelicae sinensis (dang gui), 4g 
Radix paeoniae rubrae (chi shao), 4g 
Radix paeoniae lactiflorae(bai shao), 4g 
Radix dioscoreae oppositae (shan yao), 4g 
Radix rehmanniae glutinosae conquitae (shu di huang), 4g 
Cortex moutan radicis (mu dan pi), 4g 
Sclerotium poriae cocos (fuling), 4g 
Radix dispsaci asperi (xu duan), 5g 
Semen cuscutae chinensis (tu si zi), 5g 
Fractus psoraleae corylifoliae (bu gu zhi) 5g 
Radix et caulis jixueteng (ji xue teng) 4g 
Flos carthami tinctorii (hong hua), 3g 
 
Week 4 (21 to Menses) 
 
Radix angelicae sinensis (dang gui), 4g 
Radix paeoniae rubrae (chi shao), 4g 
Radix paeoniae lactiflorae(bai shao), 4g 
Radix dioscoreae oppositae (shan yao), 4g 
Radix rehmanniae glutinosae conquitae (shu di huang), 4g 
Cortex moutan radicis (mu dan pi), 6g 
Sclerotium poriae cocos (fuling), 6g 
Radix dispsaci asperi (xu duan), 6g 
Semen cuscutae chinensis (tu si zi),6g 
Granoderma (ling zhi), 6g 
Rhizoma cyperi rotundi (xiang fu),5g 
Radix bupleuri (chai hu), 7g 
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The week 1 formula has the effect of improving menstrual bleeding and 
endometrial tissue shedding. The medicinals used move blood in the 
channels and vessels in TCM terms. 
 
The week 2 formula has the effect of nourishing blood by supplementing 
the spleen, kidneys and heart (improving folliculogenesis) in TCM terms. 
 
The week 3 formula has the effect of moving energy (qi) and warming the 
kidneys (encourages a strong ovulation) and an improved change from the 
yin follicular phase to the yang luteal phase in TCM terms.  
 
The week 4 formula has the effect of gently warming the kidney’s and 
strongly moving energy to reduce stagnation (alleviating PMS symptoms) in 
TCM terms. 
 
3.10 Treatment frequency and measurements 
Treatment frequency and measurement times for the treatment group was based on the 
standard monitored cycle diagnosis used at the WNHP for infertility cases. The range of 
standard tests and times in the menstrual cycle defines the standard fertility assessment 
protocol used (detailed below in Table 2)*. This assumes a 28 day menstrual cycle; in the 
case of shorter or longer cycles the time table is adjusted accordingly to suit each 
individual patient. 
 
Table 2, Standard monitored cycle tests - 
*
Note CD is short form for cycle day 
 
a) CD1 Baseline transabdominal (TA) and transvaginal ultrasound scan to 
identify any gross pelvic pathology and determine endometrial 
thickness and ovarian activity 
b) CD1 FSH, LH, Prolactin, oestradiol (E2) and AMH serum levels. 
c) CD9 Tubal patency ultrasound test (only if tubal patency is unknown or a 
history of PID) 
d) CD11 TV ultrasound scan to track follicle numbers and sizes 
e) CD21 TV ultrasound scan to measure endometrial thickness, corpus luteal 
vascularity and Uterine blood supply and sub endometrial vascularity. 
f) CD21 Serum progesterone level 
g) CD1-28 BBT chart 
h) CD1-28 Male partner semen analysis 
 
 
 
 
  58 
 
3.10.1 Research study cycle measurement subset 
Given this study is on patients who have previously failed IVF treatment and 
therefore have already undertaken most, if not all of the tests above and also 
this study was concerned with the use of diagnostic ultrasound in measuring the 
effectiveness of CHM on improving endometrial receptivity only a sub set of the 
above standard tests are appropriate and were collected for this study (Table 3).  
Only tests related to endometrial receptivity were included, whilst data related 
to folliculogenesis, ovulation and tubal patency was omitted.  The sub set of 
measurements used in this study is detailed below. Only this subset of data 
measurements was recorded in the study database. 
 
Table 3 - Measurements and timing of data collection used in this study 
F
i
g
  
 
FSH and progesterone were selected in addition to sub endometrial blood flow 
because of all the serum hormone measurements possible these two are widely 
accepted as the most valuable in predicting a woman’s fertility.  FSH shows 
ovarian activity and progesterone shows if a woman ovulates and the level of 
progesterone present indicates sub endometrial spiral artery dilation which is 
one factor in endometrial receptivity.  Normal FSH levels are between 3.5 IU/L 
to 12.5 IU/L and must be taken between cycle day 1 and 3 to be an accurate 
measurement and progesterone at mid luteal phase are 5.3 nmol/L to 86.0 
nmol/L . Normal endometrial thickness (ET) measurements at mid luteal phase 
are 7-15 mm. Normal levels of sub endometrial FI, VI and VFI are not possible to 
Monitored Cycle Subset Tests Used In The Study 
 
a) CD1   TA and TV scan to eliminate pathology + serum FSH level  
 
b) Ovulation + 7-9 days  TV scan to measure endometrial thickness 
and sub-endometrial  3D PDA and serum progesterone level 
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calculate as the sensitivity of a given 3D power Doppler ultrasound machine 
varies and improves with each new generation of machines.  What is critically 
important in any 3D-PDA study is the delta factor of the FI, VI and VFI indices 
measured before and after treatment and that they are taken on the same 
machine with the same power Doppler presets.  The measurements 
(progesterone, ET, sub endometrial FI, VI and VFI) must be taken between 7 and 
9 days post ovulation (DPO) to coincide with the time in the menstrual cycle 
when implantation of an embryo into the endometrium takes place in a normal 
cycle.  
 
3.11 Data acquisition 
Data acquisition for the treatment group was carried out in two phases. Each patient was 
seen a total of 4 times to collect one complete set of data (2 times before treatment and 
2 times in the third cycle of treatment). The data collection was made as part of the 
normal monitored cycle assessment protocol visits to the WNHP for all women 
presenting for infertility treatment. The subsequent treatment and progress monitoring 
for the treatment group was also part of the normal treatment protocol used at the 
WNHP for fertility patients.   
 
FSH blood draws were on cycle day 1 or 2 of each menstrual cycle  and progesterone 
blood draws were on 7-9 days past ovulation in all cases. Blood draws were carried out by 
one of the clinic’s  RGN’s from either cubital vein using the standard vaccutainer blood 
collection system.  The patient was asked to sit in a chair and a pillow was used to 
support whichever arm was selected by the RGN and then a tourniquet was applied 5-
8cm above the venepuncture site which was swabbed with a 70% isopropyl alcohol 
disposable injection site wipe, left for 30 seconds and then the venepuncture carried out. 
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The fresh blood was then couriered to The Doctors Laboratory at Whitfield Street, 
London. All reports were received in hardcopy as well as email format. 
 
 
3.11.1 Study ultrasound machine and settings 
The GE Voluson E8 ultrasound machine (Appendix F) used throughout this study 
was calibrated by GE engineers at the beginning of the study to use settings as 
close as possible to those used by Raine-Fenning et al, in their 2004 study 
defining sub endometrial 3D PDA measurements in normal women vs women 
with unexplained infertility (Raine-Fenning et al., 2004, p.330-338). However, it 
should be noted that the GE Voluson E8 is a much more sensitive 3D PDA 
scanning machine than the Kretz 530 used by Raine-Fenning et al, and so the 
recorded VI, FI and VFI index values are higher than those recorded in their 
2004 study. This is because more of the smaller capillaries in the sub 
endometrial tissue matrix are picked up by the more sensitive E8 machine. 
Ultrasound measurements and data collection was via transvaginal scans 
adhering to the British Medical Ultrasound Society (BMUS) guidelines for 
transvaginal scans and chaperones. The transvaginal sonographic examination, 
accompanied if necessary by a transabdominal examination was performed on 
all patients using the same General Electric Voulson E8 equipped with 3D, 4D 
and colour and power Doppler capability software using a 3.5-7.5 MHz convex 
4D transabdominal transducer and a 10.0-16.5 MHz endocavity 4D transducer. 
Power Doppler was applied using predetermined settings derived from the 
study of sub endometrial vascularisation carried out by Raine-Fenning et, al in 
2004 (Appendix G). These were then kept constant for every patient and 
volunteer in the study: pulse repetition frequency 1.0, power 4.0, colour gain 
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38.4, wall motion filter 75, rise 0.2, persistence 0.8, reject 82 and with a central 
frequency set to mid (Raine-Fenning et al., 2004, p.330-338). These setting were 
found to offer the best compromise between reliability , validity and time to 
define the initial volume (Raine-Fenning, 2003, p.283-291). The 3D PDA 
acquisition was at a sweep angle of 180 degrees to ensure that a complete sub 
endometrial volume was acquired using 9 degree rotation stepping (20 planes 
per acquisition sweep).  The sub endometrium was then delineated from the 
endometrium and myometrium by applying ‘shell imaging’ generating a variable 
contour that parallels the originally defined endometrial boarder surface 
contour. The study used a shell imaging contour region of 5 mm outside the 
endometrial basal layer allowing only the power Doppler signal data within the 
5 mm sub endometrial region to be measured. The selection of a 5 mm shell has 
been previously shown to reflect the inner third of the myometrium and the 
regions supplied by the radial uterine arteries (Bulletti C, 1985, p.367-371).  
Once the 3D PDA endometrial scan was complete the power Doppler signal data 
within the volume was analysed and quantified using the ‘histogram facility’ 
within GE 4DView PC software which uses specific mathematical algorithms to 
generate a set of three indices of vascularity within the acquired volume 
(Pairleitner, 1999, p.139-143).  These indices are representative of either the 
percentage power Doppler signal data within the defined volume (VI), the signal 
intensity of the power Doppler information (FI) or a combination of both factors 
(VFI) and have been shown to be representative of vascularity and flow intensity 
within an organ tissue volume (Jarvela, 2003, p.277-282).  
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Fig 3, sample 4DView screen showing 3D PDA histogram VI, FI and VFI indices calculations 
 
 
 
  
Fig 4, sample 3D PDA ultrasound image showing longitudinal, transverse and coronal 
endometrium with sub-endometrial shell region and also the 3D sub endometrial volume in 
the lower right quadrant. 
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Table 4, Power Doppler quantification.  Source: (Raine-Fenning et al., 2004, p.330-338). 
 
Vascular Index Nemonic Description 
   
Vascularlisation index VI Colour values/(colour values +grey-scale values) 
Flow index FI Weighted colour values/colour values 
Vascularlisation flow index VFI Weighted colour values/(colour values + grey-scale values) 
   
 
Table 5, g=grey-scale value in ultrasound image normalized to 0… 100; c= 
colour value in ultrasound image normalised to 0… 100;  low intensity=0; 
high intensity = 100; hg(x)= frequency of grey value x in ultrasound image; 
hc(x) = frequency of colour value x in ultrasound image . 
 
Mathematical equations used to derive vascular indices 
𝑉𝐼 =  ℎ𝑐 𝑐 ÷  ℎ𝑔 𝑔 + ℎ𝑐 𝑐 
100
𝑐=0
100
𝑔=1
100
𝑐=1
 
𝐹𝐼 =  𝑐. ℎ𝑐(𝑐)
100
𝑐=1
÷ ℎ𝑐(𝑐)
100
𝑐=1
 
 
𝑉𝐹𝐼 =  𝑐. ℎ𝑐(𝑐)
100
𝑐=1
÷  ℎ𝑔(𝑔)
100
𝑔=1
+ ℎ𝑐(𝑐)
100
𝑐=0
 
 
 
 
 
 
3.11.2 Ultrasound examination  
All ultrasound scans for the treatment group were conducted by the author 
(TAW) and a female nurse or clinical assistant was present throughout the 
ultrasound examination and at every examination. Patients were shown to a 
room by the nurse and given privacy to undress and a full length gown was 
provided to assure modesty which was worn for the entire duration of the 
examination and the nurse was present in the scanning room through the 
examination. The E8 machine was maintained and calibration checked every 6 
months throughout the study and new software updated added and the study 
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standardised power Doppler settings were reloaded at the end of each 
maintenance visit. 
 
Six data collection measurements were made for each patient before and after 
treatment: 
1) Endometrial thickness. This was measured using B mode longitudinal 
midline ultrasound examination of the uterus – measured in millimetres 
(data item 1). 
 
2) Sub-endometrial vascularity and blood flow (VI (data item 2), FI (data 
item 3) and VFI (data item 4)). This measurement was made using 3D-PDA 
measurement of the sub endometrial vascularity and then transferred to a 
notebook PC and histogram analysis made using the GE 4DVIEW software 
running on the notebook which was running Microsoft Windows Vista 
operating system. 
 
3) Serum FSH in IU/L (data item 5) and serum progesterone level in nmol/L 
(data item 6) from blood taken from a cubital vein and analysed at The 
Doctors Lab, Whitfield Street, London. 
 
3.11.3 Data recording 
Data was recorded by three mechanisms. Firstly for items 1 and 2 
measurements were taken via the in built software calculation package on the 
General Electric Voluson E8 4D ultrasound machine used in the study. The 
recorded data was then transferred to a spreadsheet on a personal computer. 
Data from the electronic lab report for item 3 was entered onto the same 
spreadsheet.  For each patient treated during the study follow-up data was 
collected twice in her third menstrual cycle after treatment commenced. This 
was at CD1 or 2 and again between 7 and 9 days post ovulation.  The data 
collected at each visit was endometrial thickness, 3D PDA sub-endometrial 
vascularity indices (FI, VI and VFI) and serum FSH and progesterone level.  The 
study period was between November 2005 and April 2008 which allowed 
sufficient time to collect data from 50 patients. The final data on pregnancy 
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outcome was counted at the end of July 2008 (3 months after the last patient 
data collection).  
 
3.12 Data analysis 
The main aim of the analysis was to compare the difference in parameters at the two 
time points, (a t-test) before and after treatment with CHM.  Because of the high degree 
of consistency in repeated data collection for the serum blood hormone assays and the 
3D-PDA ultrasound indices we can be sure that the before and after measurements are 
accurate measurements of any changes observed during the treatment period of 3 cycles.  
Thereby eliminating any compounding variables usually introduced by variability in 
ultrasound measurements taken by different operators and with different ultrasound 
machine settings. 
 
3.13 Statistical analysis methods 
As already discussed, the outcome parameters were measured on the same patients 
twice, once pre and once post treatment, in statistical terminology, this is referred to as 
paired data. All variables were measured on a continuous scale. The most appropriate 
statistical test was dependent on the distribution of the differences between pre and 
post treatment. If the differences were normally distributed, a paired t-test was the most 
suitable to compare pre and post test results. If the differences are not normally 
distributed, the Wilcoxon Matched-Pairs test was most suitable.  The results of all 
statistical analyses were determined by the size of the p-value that results from each 
parameter measured in the study. Analysis of the dataset was performed using SPSS with 
data imported from the excel spreadsheets used to record data collected in the study. 
The results of all statistical analyses were determined by the size of the p-value that 
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results from each test. A p-value of less than 0.05 is regarded as evidence of a statistically 
significant result in this study. 
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C h a p t e r  I V  
REFERENCE GROUP METHODOLOGY 
4.1 Investigation method 
The method of investigation used to assess the effects of CHM on the endometrial 
receptivity of normal healthy volunteers was determined after evaluating the same list of 
possible approaches assessed for the treatment group. Each method was defined and the 
advantages and disadvantages evaluated to determine the most suitable method to 
assess the reference group in this study.  
 
4.2 Study sample selection 
RCT’s in general are characterised by a patient sample population selected to be 
demographically and biologically representative of the general population most likely to 
contract the disease treatment being studied. The sample population would then be 
randomised into a treatment group and a control group (non treatment group).  
The treatment group would be treated with the medication under test and the control 
group a physically identical, yet therapeutically ineffective placebo.  Which patients 
receive treatment or placebo would be unknown to the patients and also, ideally, to the 
treating medical team thereby “double blinding” the study. RCT’s would not be possible 
with normal decocted CHM in liquid form as the patient and staff can see what is in the 
bags of raw herbs at decoction time with no way to hide real herbal medicine from 
placebo, however encapsulated herbal medicine in opaque capsules provides a method 
of carrying out RCT’s with CHM and this packaging and delivery system was used 
throughout this study for both the treatment group and the reference group. 
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4.3 Study design options 
In order to answer the research question “to what extent does CHM affect the 
endometrial receptivity of normal healthy women”? This part of the study was 
designed as a prospective, Double Blind RCT using the same previously proven 
physiological parameters of endometrial receptivity used for treatment group measured 
before and after treatment with CHM. The reference group part of this study is 
uncomplicated with ethical and recruitment issues as all the participants were volunteers 
and therefore a standard RCT approach could be employeed. 
 
4.4 Patient randomisation and placebo 
The reference group consisted of 50 volunteers with the same inclusion and exclusion 
criteria as the treatment group, except this group was normal healthy women, 
presumably with a normal distribution of fertility. The role this group played in the study 
was to establish what the baseline measurements of endometrial receptivity were in 
normal healthy women. The reference group was a double blinded and randomised to 
treatment or placebo and the same endometrial receptivity measurement parameters 
were taken before and after the same course of treatment for the same duration as the 
treatment group.  
 
4.5 Study design 
The study design used for the reference group was a volunteer- based RCT which was 
only possible because there are no ethical issues related to withholding treatment or 
recruiting issues with a volunteer group of healthy women. 
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4.5.1 Reference group 
There have been no previous studies of CHM effects on endometrial receptivity 
in normal healthy women so it is an important part of this study to establish the 
baseline measurements for the six parameters in normal healthy women and 
how they change when exposed to CHM. Therefore the reference group was 
used to answer the second research question “what is the effect of CHM on 
endometrial receptivity in healthy women”. Answering this question also 
establishes an important reference for future research and because the 
reference group was a volunteer group of normal healthy women they readily 
agreed to being randomised into treatment and placebo and were treated as a 
pure RCT group with the huge additional benefit of eliminating the placebo 
effect from any results obtained. The design of the study for the reference 
group fully conformed to the CONSORT guidelines for RCT studies (Altman, 
1996, p.570-571). The reference group was recruited from posters on the notice 
boards of natural medicine and conventional medicine colleges in and around 
London or referred by current patients. They were given a more extensive 
informed consent form (Appendix B) to read and sign if they wished to 
participate. The form made it clear that each participant would receive CHM 
treatment or placebo treatment at the clinic for a period of 3 menstrual cycles 
and no charge would be made for the scans, blood tests or treatment, also they 
would receive a free fertility assessment as part of their participation and the 
data collected would be confidential and used anomalously in the research 
study.  
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4.5.2 Inclusion criteria 
Healthy, normally cycling women, not taking any prescription medicine, herbal 
medicine or using any form of hormonal or intrauterine birth control, between 
20 and 45 years of age, with a BMI of 20-25, accomplished English speakers and 
an absence of known gynaecological pathology or abnormality and a CD1/2 FSH 
level of < 12 IU/L and no identified pathology at the initial pelvic ultrasound 
scan.  
 
4.5.3 Exclusion criteria 
Poor English speaker, any gynaecological pathology, a CD1/2 FSH level of > 12 
IU/L , any pathology identified at the initial pelvic ultrasound scan, taking any 
medications (pharmaceutical or herbal) or using any form of hormonal or 
intrauterine birth control, younger than 20 or older than 45 and with a BMI of 
less than 20 or over 25. 
 
4.5.4 Sample size calculation 
Since there are no previous studies carried out using CHM to investigate its 
effect on normal endometrium receptivity except our 2005 pilot study, the 
sample size was selected on the basis of a power calculation related to the 
degree of statistical change in endometrial parameters seen in our pilot study 
(Appendix C). Allowing for attrition of 5-10% (for a well motivated group) 55 
volunteers were recruited. In reality there was no drop out from this group so 
only the first 50 volunteer’s data was included in the final analysis. 
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4.6 Interventional treatment 
The reference group was randomised into a placebo arm and a treatment arm with the 
placebo arm receiving encapsulated ground rice instead of CHM and the treatment arm 
receiving individualised CHM formulas in an identically way to the treatment group. The 
same sets of physiological changes were measured before and after the course of 
treatment with either CHM capsules or placebo capsules as follows: 
 
The reference group treatment arm (25 volunteers) received the same 
individualised four phase menstrual cycle herbal medicine formula (same as 
the treatment group). Delivery mechanism was the same 500mg opaque 
vegetable capsules and the dose was again 3-5 g per day (3,4 or 5 capsules 
twice daily). 
 
The reference group placebo arm (25 volunteers) received granulated rice 
which has no medicinal function in CHM and this was again prepared into 500 
mg opaque vegetable capsules all received the same dose of 3 g per day (3 
capsules twice daily).  
 
4.7 Medicinals and randomisation  
The base formula used for the reference group treatment arm was identical to the 
formula used for the treatment group of failed IVF patients detailed in section 3.12 with 
the same additions and subtractions and doses of individual medicinals based on the 
patients diagnosis and pattern discrimination. Each volunteer was diagnosed and treated 
as if they were going to receive CHM treatment with the final individualised formula for 
each volunteer sent to the pharmacy and only at that point was the randomisation 
applied by the pharmacy and either CHM or placebo capsules produced and sent to the 
volunteer. A database was set up at the pharmacy containing a table with a capacity of 80 
patients to take part in the study. Each of the table entries was allocated randomly by a 
computer programme and a status to determine if it would be a placebo or normal herbal 
prescription. Whenever a new patient entered the study, the computer randomly 
assigned the patient to an entry in the table to determine if the patient should receive 
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placebos or normal prescription.  The information was recorded in the patient database 
and the dispenser was instructed by the computer which type of prescription to issue. No 
one but the dispenser of the prescription was aware of the type of prescription. The 
prescription carried an ID number which could be used to check back in the database to 
determine if the prescription were normal or a placebo. This allowed for identification by 
the dispenser in case of emergency. Each label contained a pharmacy emergency phone 
number should healthcare workers or the patient need to know if her particular container 
was prescription or placebo. 
 
The labels on the containers for the reference group were identical in both placebo and 
treatment arms listing all the medicinals in the prescribed formula and clearly showing 
that the container MAY only contain placebo ground rice capsules (Appendix E).  
A pharmacy generated code on the container being the only identifier as to which has 
placebo and which has treatment medicinals. The records of each formula and who was 
given placebo or CHM were maintained by volunteer name only at the pharmacy making 
up the medicines and so the study was blinded to all the clinic staff and volunteers 
(double blinded). Only at the conclusion of the study were the records of who received 
placebo or herbal medicine supplied to the author for statistical analysis. 
 
4.8 Measurement sub set 
The same subset of tests used in the treatment group was used again in the reference 
group related to endometrial receptivity (Table 6). Only this subset of data 
measurements was recorded in the study database.  
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Table 6 - Measurements and timing of reference group data collection 
  
 
 
 
 
 
4.9 Data acquisition 
Data acquisition for the reference group was carried out in two phases. Each volunteer 
was seen a total of four times to collect one complete set of data (two times before 
treatment and two times in the third menstrual cycle of treatment. The data collection 
was carried out on specific study related visits to the clinic for each volunteer. One visit 
was required for each volunteer before they were enrolled in the study (or were 
excluded) on CD1/2 of their menstrual cycle for a scan to eliminate pathology and to 
check FSH level (if there was no pathology and the FSH was less than 12 IU/L, this visit 
served as the first of the two visits to collect pre treatment data). This was then followed 
by another visit in the same cycle at 7-9 days post ovulation as measured by LH surge 
urine tests taken by the volunteer at home. She then came in 8-10 days after the positive 
LH surge stick (equalling 7-9 days post ovulation).  Then two further visits were required 
during treatment, one at CD1/2 of the third menstrual cycle of treatment and one at 
ovulation + 7-9 days (determined by LH surge urine tests), again in the third menstrual 
cycle following start of treatment. At this point treatment (or placebo) was discontinued 
for the reference group volunteers.  
 
FSH blood draws were on cycle day 1 or 2 of each menstrual cycle and progesterone 
blood draws were on 7-9 days past ovulation in all cases. Blood draws were carried out by 
one of the clinic’s  RGN’s from either cubital vein using the standard vaccutainer blood 
collection system.  The volunteer was asked to sit in a chair and a pillow was used to 
Monitored Cycle Subset Tests Used In The Study 
 
c) CD1   TA and TV scan to eliminate pathology + serum FSH level  
 
d) Ovulation + 7-9 days  TV scan to measure endometrial thickness 
and sub-endometrial  3D PDA and serum progesterone level 
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support whichever arm was selected by the RGN and then a tourniquet was applied 5-
8cm above the venepuncture site which was swabbed with a 70% isopropyl alcohol 
disposable injection site wipe, left for 30 seconds and then the venepuncture carried out. 
The fresh blood was then couriered to The Doctors Laboratory at Whitfield Street, 
London. All reports were received in hardcopy as well as email format. 
 
 
4.9.1 Ultrasound examination  
All ultrasound scans for volunteers were carried out using identical machine 
settings and measurements taken in the treatment group. This was again 
conducted by the author (TAW) and a female nurse or clinical assistant was 
present throughout the ultrasound examination and at every examination and 
the volunteer given exactly the same privacy and a grown to wear as in the 
treatment group. The initial scan and FSH level test was carried out to 
determine if the volunteers met the study inclusion criteria. A standard baseline 
pelvic diagnostic ultrasound scan was carried out examining uterine size, echo 
structure; ovarian shape, size and morphology were examined and longitudinal 
(LD), transverse (TD) and anteroposterior (APD) diameters were measured and 
volumes calculated by means of a prolate ellipsoid formula: volume = 0.5233 x 
LD x TD x APD in mm. Any irregular findings were recorded and any ovarian or 
uterine pathology were also recoded. This follows the BMUS standard protocol 
guidelines for a diagnostic pelvic ultrasound scan. For each patient and 
volunteer treated during the study follow-up data was collected twice in her 
third menstrual cycle after treatment commenced. This was at CD1 or 2 and 
again between 7 and 9 days post ovulation.  The data collected at each visit was 
endometrial thickness, 3D PDA sub-endometrial vascularity indices (FI, VI and 
VFI) and serum FSH at CD1/2 and progesterone level at 7-9 days post ovulation. 
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The same six data collection measurements were made for each volunteer 
before and after treatment or placebo: 
1) Endometrial thickness. This was measured using B mode longitudinal midline 
ultrasound examination of the uterus – measured in millimetres (data item 
1). 
 
2) Sub-endometrial vascularity and blood flow (VI (data item 2), FI (data item 3) 
and VFI (data item 4)). This measurement was made using 3D-PDA 
measurement of the sub endometrial vascularity and then transferred to a 
notebook PC and histogram analysis made using the GE 4DVIEW software 
running on the notebook which was running Microsoft Windows Vista 
operating system. 
 
3) Serum FSH in IU/L (data item 5) and serum progesterone level in nmol/L 
(data item 6) from blood taken from a cubital vein and analysed at The 
Doctors Lab, Whitfield Street, London. 
 
4.9.2 Data collection 
Data was recorded by the same three mechanisms as the treatment group (see 
section 3.14.3) and the study period was between November 2005 and April 
2008 allowed sufficient time to collect data complete sets of data from the 50 
volunteers.  
 
4.10 Data analysis 
The main aim of the analysis was to compare the difference in parameters at the two 
time points, (a t test) in the reference group.  Because of the high degree of consistency 
in repeated data collection for both the serum blood hormone assays and the 3D-PDA 
ultrasound indices we can be sure that the before and after measurements are accurate 
measurements of any changes observed during the treatment period of 3 cycles thereby 
eliminating the compounding variables usually introduced by variability in ultrasound 
measurements taken by different operators and with different ultrasound machine 
settings. 
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4.11 Statistical analysis methods 
The outcome parameters for the reference group were measured on the same patients 
twice, once pre and once post treatment, in statistical terminology, this is referred to as 
paired data. All variables were measured on a continuous scale. The most appropriate 
statistical test is dependent on the distribution of the differences between pre and post 
treatment. If the differences are normally distributed, a paired t-test is most suitable to 
compare pre and post test results.  If the differences were not normally distributed, the 
Wilcoxon Matched-Pairs test was most suitable.  The results of all statistical analyses 
were determined by the size of the p-value that results from each parameter measured in 
the study. Analysis of the dataset will be performed using SPSS with data imported from 
the spreadsheets used to record data collected in the study. The results of all statistical 
analyses were determined by the size of the p-value that results from each test. A p-value 
of less than 0.05 is regarded as evidence of a statistically significant result in this study. 
 
4.12 Overall study group organisation 
The combination of the two parallel groups answers both research questions posed for 
this study with the treatment group providing data on the effects of CHM on women who 
repeatedly fail IVF and are diagnosed with unexplained infertility. In addition the 
reference group provided baseline reference measurement values for healthy women 
before and after treatment with CHM. Fig 5 shows the whole study organisation and the 
relationship of measurements used in this study. 
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Fig 5. Two parallel sample groups, one failed IVF treatment group and one randomised healthy women group. 
Sample size in total is 100 and identical pre and post treatment measurement metrics. 
 
 
4.13 Study funding and sponsorship 
The entire study was funded by the author with no external funding or sponsorship. All 
herbal medicines were provided to the reference group at no charge as were blood tests 
and ultrasound examinations. The treatment group were charged for their treatment as 
normal as their treatment was not changed or effected in anyway whatsoever. It is worth 
commenting that after filing the application for ethics approval on the COREC website at 
the proposal stage of this study the author was contacted by one large pharmaceutical 
company and pressure was exerted to discourage the author from continuing the study. 
Costs were £472 per volunteer x 50 = £23,600 plus lost billable time in the clinic of 150 
hours = £18,000 - Total study cost = £41,600  
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4.14 Methodology summary 
An extensive search of the literature suggested that until now there have been no 
published placebo-controlled double blind studies into CHM in the area of fertility, 
endometrial receptivity and early implantation failure. There is however, a large number 
of clinical case series studies providing us with interesting findings widening the basis of 
our scientific research in this field; in fact, they help to concretise indications and 
application forms in CHM, thus also determining their value and position. However there 
was insufficient robust evidence to confirm, or refute, the effectiveness of CHM to 
enhance endometrial receptivity of failed IVF patients with unexplained infertility or 
indeed in normal healthy women. This study investigated the difference in a 
predetermined set of measurements of endometrial receptivity (FSH, progesterone, ET, 
sub endometrial FI, VI and VFI) it was not possible to conduct a pure RCT because of 
shortage of failed IVF participants and ethics committee support.  It was therefore 
decided to use a prospective longitudinal interventional “t test” before and after 
treatment measurement study for failed IVF patients attending the WNHP for treatment 
with CHM and a parallel interventional randomised controlled trail study of non-
pathological women volunteers measured with the same before and after treatment with 
CHM or placebo in order to establish baseline reference endometrial receptivity data for 
normal health women. 
 
It is the intention of the author to contribute to the body of knowledge relating to CHM 
effectiveness and safety with scientifically rigorous data by publishing the results of this 
study in peer reviewed TCM journals and peer reviewed conventional medicine journals 
in 2009 and presenting the study results at, at least one conventional medicine 
gynaecology conference and one TCM conference. 
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C h a p t e r  V  
RESULTS 
5.1 Introduction 
Two parallel studies were performed examining the effectiveness of CHM. One study was 
performed on a group of failed IVF patients attending the Women’s Natural Health 
Practice for treatment (the treatment group), whilst a second was performed on a group 
of screened healthy volunteers with no reproductive pathology, (the reference group). 
The outcome measures were the change in six endometrial receptivity related 
parameters over time and pregnancy rate post treatment. The differences between pre-
treatment and post-treatment values were used as the outcome measures in all analyses. 
The raw data collected is presented in Appendix H. 
 
Fig 6. Flow chart showing study sample composition. 
 
Assessed for eligibility – N=143
Excluded 
did not meet eligibility criteria  N=43
Treatment Group  
Failed  IVF patients
N=50
Reference Group 
Normal volunteers
N=50
Received  
treatment with 
CHM for 3 cycles
Included in analysis
N=50
Lost to follow-up 
N=0
Pregnant  N= 17
Live births N=10
Randomised to 
placebo   N=25
Randomised to 
treatment N=25
Received  
treatment  with 
placebo for 3 
cycles
Received  
treatment with 
CHM for 3 cycles
Lost to follow-up 
N=0
Lost to follow-up 
N=0
Included in analysis
N=25
Included in analysis
N=25
STUDY FLOW CHART
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Baseline line characteristics for the two groups at enrolment showed that the mean (± s.e 
mean) age of the two groups was 41.4 ± 0.46 for the treatment group and 28.1 ± 0.66 for 
the reference group. The number of failed IVF cycles was a mean of 3 for the treatment 
group, BMI was a mean of 24 for the treatment group and 22 for the reference group, all 
participants in both groups were good English speakers, FSH mean levels were an average 
of 9.7 for the treatment group and 6.1 for the reference group. All participants in the 
treatment group were pathological having failed at least 2 IVF cycles in previous 2 years 
and diagnosed with unexplained infertility whilst none of the reference group had any 
pathology after initial intake screening. None of the participants in either group were 
using any type of hormonal or intrauterine birth control, all 50 of the reference group 
were either already using a barrier birth control method (condom, cervical cap or 
diaphragm) or agreed to do so for the duration of the study. None of the participants in 
either group were taking any prescription medicines. 
 
Table 7 – General characteristics of the two groups of participants 
 
Baseline 
Characteristics 
Treatment Group 
Mean (Range) ± SEM 
 
Reference Group 
Mean (Range) ± SEM 
 
   
Age  42.4 (32-46) ±0.46 28.1 (20-39) ±0.66 
Number failed IVF 3 (2-5) 0 
BMI 24 (20-25) 22 (20-25) 
English speaking 50 50 
FSH  9.7 (8.1-11.2) ±0.44 6.1 (4.8-7.4) ±0.37 
Gynae pathology 
Hormonal or IUD BC 
Prescription drugs 
50  
0 
0 
 
0 
0 
0 
 
   
 
Median age for Treatment Group = 42 years 
Median age for Reference Group = 27.5 years 
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5.2 Statistical methods 
Treatment group 
The first set of analyses examined the change in values over time for the treatment group 
of infertile women. All outcomes were measured on a continuous scale, and an 
examination of the data indicated that the change over time was normally distributed for 
all outcomes. As a result, the paired t-test was used to compare between the two 
occasions. 
 
Reference group 
The second set of women consisted of the reference group of healthy volunteers, who 
were randomly given either CHM or a placebo treatment. An examination of the 
distribution of the changes over time indicated that all were approximately distributed. 
However, there was generally found to be a wider spread of measurements in the 
treatment group than in the reference group. Therefore, the standard two-sample t-test 
is not suitable for these comparisons, as it assumes equal variance in the two groups. 
Therefore, a variation of the t-test that allows the spread of values to be different in the 
two groups was used instead. This test is often referred to as a Welch test.  
 
The reference group provided important baseline data on pre treatment measurement 
values for normal women. This then became the base from which improvements after 
treatment in the reference group and improvements after intervention in the treatment 
group were assessed. 
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Abbreviations 
ET  Endometrial thickness (mm) 
SE VI  Sub endometrial vascularity index (calculated index) 
SE FI  Sub endometrial flow index (calculated index) 
SE VFI Sub endometrial vascularity flow index (calculated index) 
FSH Follicle stimulating hormone (IU/L) 
PROG progesterone (nmol/L) 
 
Note: For FSH to be lowered ovarian oestradiol production and/or transport must 
increase. For oestradiol to increase either antral follicle numbers or size or both must have 
increased. 
 
5.3 Baseline measurements - Reference group 
The baseline measurements taken before any treatment for the Reference group showed 
a mean endometrial thickness of 10.3 mm, a mean Velocity Index of 3.05, a mean Flow 
Index of 36.4, a mean Velocity Flow Index of 1.4, a mean FSH of 6.1 IU/L and a mean 
progesterone level of 46.4 nmol/L. This set of data therefore establishes the reference 
level in normal healthy women (Table 8). 
 
Table 8– Baseline values for Reference group taken before treatment 
 
 
 
 
5.4 Treatment group results 
The paired t-test was used to compare the results between the two occasions, and a 
summary of the results is given in the subsequent table (Table 9). The first figures are the 
mean (standard deviation) value at both the pre and post times. Also tabulated are the 
   
Variable Baseline Pre-treatment  
Mean (SD) ± SEM 
  
ET 10.3 (2.4) ±0.34 
SE VI 3.05 (0.38) ±0.5 
SE FI 36.40 (2.91) ±0.41 
SE VFI  1.40 (0.20) ±0.3 
FSH 6.1 (2.6) ±0.37 
PROG 46.4 (10.9) ±1.54 
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mean changes over time, and corresponding 95% confidence interval. The changes were 
calculated as value post-treatment minus value pre-treatment, and so a positive change 
indicates an increase in values over time. Also reported are the p-values indicating the 
significance of the results. 
 
Table 9 – Comparison between pre and post intervention for the Treatment group 
 
Variable Pre-treatment 
Mean (SD) n=50 
Post treatment 
Mean (SD) n=50 
Change 
Mean (95 %CI) 
P-value 
     
ET 8.2 (2.5) 9.4 (2.3) 1.2 (0.8, 1.5) <0.001 
SE VI 1.96 (0.27) 2.09 (0.20) 0.13 (0.09, 1.16) <0.001 
SE FI 36.76 (0.93) 37.33 (0.95) 0.57 (0.43, 0.71) <0.001 
SE VFI  0.87 (0.28) 1.05 (0.29) 0.18 (0.13, 0.22) <0.001 
FSH 9.7 (3.1) 8.8 (3.2) -0.9 (-1.2, -0.6) <0.001 
PROG 36.5 (10.8) 41.3 (10.9) 4.9 (3.2, 6.5) <0.001 
     
 
 
The results indicated that in the Treatment group there was a highly statistically 
significant difference between pre and post treatment results for all variables examined 
(p < 0.001).  For all variables, with the exception of FSH, there was an increase in values 
over time indicating an improvement in endometrial receptivity. For example the ET 
parameter increased by 1.2 mm on average, whilst the SE VI parameter increased by 0.13 
units. The exception was FSH, where there was a significant decrease (p < 0.001) in 
values. For this variable, there was a mean decrease of 0.9 units from pre to post 
treatment. A reduction in FSH is a positive finding. 
 
5.5 Reference group results 
The Welch test was used to compare the change in scores between the treatment and 
placebo arms, and a summary of the results is given in the subsequent table (Table 9). The 
figures reported are the mean and standard deviation change in each group, together 
with a p-value indicating the significance of each result. The changes are reported as 
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value post-treatment minus value pre-treatment, so a positive change implies an increase 
in values over time. 
 
Table 10 – Comparison post treatment between placebo and treatment arm for the Reference group – Mean 
(SD), N =25 
 
Variable Placebo Arm 
Mean (SD) 
Treatment Arm 
Mean (SD) 
P-value 
    
ET -0.19 (0.50) 1.55 (1.08) <0.001 
SE VI 0.06 (0.15) 0.22 (0.21)  0.003 
SE FI 0.17 (0.96) 0.41 (2.69) 0.68 
SE VFI  0.03 (0.12) 0.17 (0.20)  0.004 
FSH 0.17 (0.53) -0.37 (0.64)  0.002 
PROG 0.36 (3.09) 3.56 (6.90) 0.04 
    
 
 
The results indicated that the change in scores varied significantly between the two arms 
(treatment and placebo) for all measures, with the exception of SE FI, where there was no 
significant difference between arms. Where a significant difference was found, in the 
majority of cases, the values were higher in the treatment arm than in the placebo arm. 
For example, for SE VI the change over time was an increase of 0.06 units in the placebo 
arm, but an increase of 0.22 units in the treatment arm. The exception was again for FSH, 
where the change for the treatment arm was lower than for the placebo arm, which is a 
positive finding. There was an increase of 0.17 units over time for the placebo arm, but a 
decrease of 0.37 units over time for the treatment arm indicating an improvement in 
ovarian response. 
 
Reference group – summary  
Summary statistics are presented for both arms, both pre-treatment and post-treatment 
for all variables (Table 11). The figures given are the mean and standard deviation both 
the pre and post treatment for both arms. 
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Table 11 – Summary post treatment results comparison of pre and post intervention for the Reference group - 
Mean (SD) 
 
 Placebo Arm  Treatment Arm 
Variable Pre 
Mean (SD) 
Post 
Mean (SD) 
Pre 
Mean (SD) 
Post 
Mean (SD) 
     
ET 10.3 (2.4) 10.1 (2.5) 10.1 (2.6) 11.6 (2.6) 
SE VI 3.05 (0.38) 3.11 (0.44) 3.09 (0.50) 3.31 (0.45) 
SE FI 36.40 (2.91) 36.58 (2.84) 36.18 (4.03) 36.58 (4.77) 
SE VFI  1.40 (0.20) 1.43 (0.25) 1.42 (0.20) 1.60 (0.26) 
FSH 6.1 (2.6) 6.3 (2.8) 5.9 (2.1) 5.4 (2.0) 
PROG 46.4 (10.9) 46.8 (11.3) 46.0 (12.7) 49.5 (11.8) 
     
 
 
5.6 Exploring the data  
This research project consisted of two studies carried out in parallel. One study was 
performed on a group of failed IVF patients (the Treatment Group), whilst a second was 
performed on a group of healthy, non pathological volunteers (the Reference Group).  
The results of the statistical analysis of the two individual groups have already been 
presented above.   In this section to explore the data further, all three patient groups 
were compared simultaneously to understand if anything more can be learned from the 
data collected. 
 
All outcomes were measured on a continuous scale, and the main objective was to 
compare between the three groups of subjects. Therefore, analysis of variance (ANOVA) 
was used to compare between the three groups. Subsequently the specific difference 
between each pair of groups was examined using the Sidak post-hoc test. This compares 
between each pair of groups, but also adjusts the p-values to take account of multiple 
comparisons for each outcome. 
 
Analyses were performed for pre-treatment, post-treatment and the change from pre to 
post-treatment measurements. 
 
  87 
 
 
 
 
ANOVA was used to compare the results between the three groups, and a summary of 
the results is given in table 12. The figures are the mean (standard deviation) value for 
each group, and the p-value indicating if there is an overall difference between the three 
groups. 
 
Table 12 – Analysis of variance between all three groups - Mean (SD) 
 
Time Variable TG vs. RG Placebo TG vs. RG Treat RG Placebo vs. 
RG Treat 
     
Pre ET   0.003 0.01 0.98 
Treatment SE VI <0.001 <0.001 0.97 
 SE FI 0.92 0.73 0.99 
 SE VFI  <0.001 <0.001 0.98 
 FSH <0.001 <0.001 0.99 
 PROG   0.001   0.003 0.99 
     
Post ET 0.56   0.001 0.10 
Treatment SE VI <0.001 <0.001 0.17 
 SE FI 0.63 0.64 1.00 
 SE VFI  <0.001 <0.001 0.11 
 FSH <0.001 <0.001 0.80 
 PROG 0.14 0.01 0.78 
     
Pre to Post ET <0.001 0.37 <0.001 
Treatment SE VI 0.20 0.05   0.001 
 SE FI 0.61 0.96 0.92 
 SE VFI    0.001 1.00   0.007 
 FSH <0.001 0.03 0.20 
 PROG   0.004 0.71 0.13 
     
 
 
The results shown in table 12 indicated that there was a highly statistically significant 
overall difference between the three groups at all stages for the majority of variables. The 
exception was for SE FI which was not found to vary between groups for at of the times 
examined. 
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Post-hoc tests were performed to examine between pairs of groups, and the p-values 
from these Sidak tests are given in table 13. 
 
 
Table 13 – Analysis of variance between the pairs of groups - Mean (SD) 
 
Time Variable TG vs. RG Placebo TG vs. RG Treat RG Placebo vs. 
RG Treat 
     
Pre ET   0.003 0.01 0.98 
Treatment SE VI <0.001 <0.001 0.97 
 SE FI 0.92 0.73 0.99 
 SE VFI  <0.001 <0.001 0.98 
 FSH <0.001 <0.001 0.99 
 PROG   0.001   0.003 0.99 
     
Post ET 0.56   0.001 0.10 
Treatment SE VI <0.001 <0.001 0.17 
 SE FI 0.63 0.64 1.00 
 SE VFI  <0.001 <0.001 0.11 
 FSH <0.001 <0.001 0.80 
 PROG 0.14 0.01 0.78 
     
Pre to Post ET <0.001 0.37 <0.001 
Treatment SE VI 0.20 0.05   0.001 
 SE FI 0.61 0.96 0.92 
 SE VFI    0.001 1.00   0.007 
 FSH <0.001 0.03 0.20 
 PROG   0.004 0.71 0.13 
     
 
The results showed that at pre-treatment there was a difference between the Treatment 
Group and each of the two Reference Groups for all variables apart from SE FI where 
there was no difference. In each case the Treatment Group had lower values that the 
Reference Groups, with the exception of FSH where the Treatment Group had higher 
values. There were no differences between Reference Groups at pre-treatment. 
 
The post treatment results also indicated significant differences between the Treatment 
Group and Reference Groups, but this time, not for so many measures. The Treatment 
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Group differed from the Reference placebo group for SE VI, SE VFI and FSH, whilst the 
Treatment Group varied from the Reference treatment group for all outcomes apart from 
SE FI. Again there were no differences between the two Reference Groups. 
 
The results for the change from pre to post treatment showed differences between the 
Treatment Group and Reference placebo group for all measures with the exception of SE 
VI and SE FI. Where changes were observed, these were greater for the Treatment Group, 
except for FSH where the change was greater in the Reference placebo group. Unlike the 
pre and post treatment results, there were generally no differences between the 
Treatment group and Reference treatment group. The exception was for FSH. The two 
Reference Group treatments were found to vary for ET, SE VI and SE VFI, and in each case 
the change was greater in the treatment group than in the control group. 
 
 
5.7 Pregnancy outcome 
The number of pregnancies achieved in the group of 50 failed IVF patients at 6 months 
post commencement of the last patient or volunteer was 17 pregnancies (July 7th 2008),  
10 live births, 2 miscarriages and 5 ongoing pregnancies (34% pregnancy rate).  The 
timing of the treatment group +ve pregnancy tests post commencement of treatment 
were, 1 at week 8, 1 at week 12, 1 at week 14, 1 at week 19 , 1 at week 20, 2 at week 21, 
4 at week 22, 3 at week 23 and 3 at week 24. The reference group pregnancy rate was 
not measured as this is irrelevant to this study as this group was for the most part 
avoiding pregnancy. Treatment continued after 6 months but outside this study. 
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Fig 7. Treatment group pregnancy outcome over time. 
 
5.8 Participant attrition and qualification elimination 
There were no study drop-outs, none of the patients agreeing to allow the data from 
their treatment to be used in this study withdrew consent. Forty three volunteers failed 
to qualify across both the treatment group and the reference group because either 
pathology was discovered at the initial inclusion screening scan or volunteers did not 
meet inclusion criteria. 
 
5.9 Adverse reactions and side effects 
The facility was provided to all participants in this study to report any adverse reactions 
on the RCHM yellow card system and in addition each participant was verbally asked at 
each clinic visit if they had experienced any adverse reactions whilst taking CHM. There 
were no adverse reactions or side effects reported from any participants in either the 
treatment group or the reference group. 
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5.10 Limitations 
All ultrasound measurements were taken on one E8 machine which was calibrated to 
3D PDA settings as close as possible to those used by Raine-Fenning et al (2004) study 
of sub endometrial blood flow in women with impaired fertility.  The interobserver 
reliability and validity of volume calculation from three-dimensional ultrasound 
datasets in the in vitro settings has been well explored by Raine-Fenning et al (2003) 
who demonstrated that unlike 2D power Doppler assessment of blood flow in an organ, 
3D PDA gives highly reliable and repeatable measurements, even between multiple 
operators.  There are inherent problems with any study where measurements are 
taken by the same operator (as is the case in this study).  The operator was not blind to 
the measurements being taken, however any mistakes in technique are minimised as 
the process of taking a 3D scan of an organ is mechanical without much operator skill 
involved. The operator places the probe in one position over the organ to be imaged 
and the sweep and data acquisition is then performed automatically under machine 
control.   Regarding the effects on the study of non-blinded 3D PDA data collection, the 
measurement histological analysis was made after the actual scan to collect the data in 
4D View (an 3D ultrasound analysis software package) on a separate PC and at a 
separate time.  Therefore it was almost impossible to relate the data being analysed in 
the PC package to the actual data collection scan performed on the patient or 
volunteer.    
 
The treatment group was taken from women who had self selected to follow TCM 
infertility treatment after conventional assisted reproductive treatment had failed and 
they had been given the diagnosis of unexplained infertility in conventional medicine 
terms. This means the sample is not at all representative of the general population with 
fertility problems, being heavily slanted towards the 20% in the unexplained infertility 
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category (those having unexplainable problems conceiving).  It could be argued that 
this makes the findings even more relevant and possibly the results would be even 
more encouraging if the sample was taken from women enrolling for conventional IVF 
treatment and conduct the same study on that sample group. All the women in the 
reference group of the study knew that they would receive treatment after the 
monitored cycle and then be measured again after the treatment had taken place. 
 
 Therefore one could argue that any improvement was due to a ‘psychological placebo 
effect’ because the women thought they were getting a new innovative treatment. The 
reduction in anxiety and new hope alone could be sufficient to cause some 
improvement in the fertility indicators measured as we know stress is an important 
factor in infertility. Another possible explanation for a positive effect observed in the 
treatment group could be a ‘time effect’, where because the patient has been receiving 
treatment previously there is a cumulative effect of physiological changes taking place, 
one could expect an improvement in their fertility over time, regardless of the 
treatment administered. Verifying this would require a sub-section of the sample 
becoming a control group receiving no treatment whatsoever and measuring their 
fertility indicators over the same time period. This would be difficult to implement 
given the ethical issues already discussed although should be considered further in 
future studies. 
 
Compliance to the treatment being given must also be recognised as a limitation of this 
study.  Each patient in the Treatment group was given 4 containers for each menstrual 
cycle (12 in all), with capsules containing either herbal medicine (or for the Reference 
group herbal medicine or placebo) and the responsibility for taking the capsules daily 
was that of the patient or volunteer.  It is possible that some of each group did not take 
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the capsules consistently each day or did not take the prescribed amount of capsules 
each day.  It is unlikely that the Treatment group was non-compliant as this group was 
highly motivated to complete treatment because CHM was in most cases their last 
chance to achieve a pregnancy with their own eggs.  However this is not the case in the 
Reference group consisting of volunteers and with no real motivation to comply with 
the prescribed treatment.  There is some encouragement in that none of the volunteers 
in the reference group dropped out of the study,  which would indicate that they were 
motivated to at least complete the three months of treatment.  Of course if the treated 
arm of the Reference group  were non compliant to some extent, taking reduced 
amounts of capsules or skipping days that could be one explanation for the reduced 
improvements seen in the Reference group.  A solution should be sought to the 
compliance issue in any further research carried in similar studies.  In hind sight a 
questionnaire could have been given to each participant to find out views about 
“swallowing” large amounts of capsules so often, how many times they forgot, how 
many times they took reduced numbers of capsules etc. 
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C h a p t e r  V I  
 DISCUSSION 
 
6.1 Description of results 
The results from this study showed statistically significant changes in all six parameters 
affecting endometrial receptivity in the treatment group and five out of six parameters in 
the reference group. However, the improvements in treatment group were considerably 
more significant than in reference group which is not surprising as this is the reference 
group of normal healthy women and improvements in non-pathological women would 
not be expected to be as significant as in pathological women. 
 
6.1.1 Treatment group  
For the six parameters measured before and after treatment all six were 
statistically significant each with P values of  < 0.001. The increase in ET was a 
mean of 1.2 mm and the sub endometrial vascularity as measured by the three 
parameters VI, FI and VFI were all significant with FI increasing the most with a 
mean increase of 0.57. Together these 4 aspects of the endometrium define a 
clear improvement indicating an improvement in the overall quality of the 
endometrial tissue. Because the CHM formula used contain many blood related 
medicinals and their effects are known to improve blood quality and flow it is 
reasonable to assume that it is these medicinals which contributed to overall 
endometrial improvement. Without much more specific research and analysis 
of the formula from a biomedical science point of view it is impossible to say 
more about why this may be the case.  What we can say is that the parameters 
which measure endometrial blood flow did indeed improve significantly after 
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treatment in the treatment group and also to a lesser extent in the reference 
group treatment arm and not at all in the placebo arm.  
 
The reduction in FSH from a mean of 9.7 IU/L pre treatment to a mean of 8.8 
IU/L indicated that the anterior pituitary gland secretions of FSH were lower in 
response to improvement in oestradiol production in turn from improved antral 
follicle development (size and number). This may also be the result of the same 
medicinal effects of improved blood flow, but in this case improved blood flow 
to the ovaries. This effect was not measured in this study, but should be 
investigated in the future. It is also possible that CHM has a more profound 
effect directly on the process of recruiting primordial follicles and their 
development. It is clear that if more and larger antral follicles exist then the 
increased oestradiol secreted would improve endometrial development in the 
follicular phase of the cycle resulting in both reduced FSH and also improved 
endometrial receptivity. Progesterone also increased from a mean of 36.5 
nmol/L to a mean of 41.3 nmol/L, indicating an improvement in the CL function. 
Again this could possibly be from the effects of the blood related medicinals 
resulting in increased vascularity in the CL which in turn improved corpus 
luteum progesterone production. It has already been demonstrated that higher 
progesterone levels improve endometrial spiral artery function allowing more 
blood flow to the endometrial tissue in turn improving endometrial receptivity. 
It has also been previously demonstrated that reduced progesterone is 
associated with early pregnancy miscarriage. However we did not assess the 
corpus luteum in any other way apart from serum progesterone levels in this 
study. There is clear justification for more research specifically on CHM effects 
on the corpus luteum. What can be deduced is the increase in progesterone in 
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the luteal phase of the cycles in these patients also contributed to the improved 
endometrial receptivity.  This also suggests that there maybe a role for CHM in 
natural IVF cycles in improving post embryo transfer production of endogenous 
progesterone as previous workers have already shown that the artificial corpus 
luteum from aspirated follicles is far less functional hence the need for 
progesterone supplementation post embryo transfer (Tavaniotou et al., 2002, 
p.123-130). 
6.1.2 Reference group 
The same six parameters were measured in the reference group as in the 
treatment group before and after treatment or placebo. The pre treatment 
measurements showed very similar levels in all six parameters statistically with 
the post treatment measurements when the placebo and treatment arms were 
compared showed five out of six parameters were statistically significant with P 
values all < 0.05.  The one measurement which failed to meet statistically 
significance was SE FI (P = 0.68), however four out of the six did achieve P values 
of < 0.005. This shows that although the velocity of blood flow significantly 
improved and the volume of flow did increase, but not sufficiently to become 
statistically significant. This suggests that the amount of blood circulating in the 
sub endometrium was not significantly improved in normal healthy women by 
CHM, yet the velocity of that blood flow did significantly increase. This suggests 
that the circulating blood flow improvements in the pathological treatment 
group could be a major factor in the pregnancy rate outcome measurement. 
More research would be needed to establish if this is the case. The combination 
of velocity (VI) and volume (FI) when measured as a combined index (VFI) did 
achieve statistical significance.  The reference group was double blinded to 
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patients and staff alike and although the improvements were much less 
significant than in the treatment group of infertile women the results indicate 
that endometrial receptivity can be improved, but to a lesser degree in normal 
healthy fertile women.  When analysed in their own right as a standalone group 
the findings are never the less positive showing that CHM can improve normally 
fertile women’s fertility presumably therefore they could expect to achieve 
pregnancy rates better than the generally accepted 15% per menstrual cycle 
which are the statistics for the healthy fertile female population in general. The 
same medicinals were used in the reference group treatment and it is most 
likely that the same effects on blood flow took place resulting in the 
improvement in sub endometrial blood flow.  FSH also reduced (but to a lesser 
degree) in this group indicating that CHM also had a positive effect on follicle 
development and oestradiol levels and therefore endometrial thickness. The 
same can be said about the increase in progesterone levels and the positive 
effects on the endometrial spiral artery function. The reference group findings 
are in addition to being significant in their own right helpful in how we should 
think about the treatment group results. Looking at both groups side by side the 
data suggests that CHM helps pathologically infertile women more than normal 
fertile women which is an important additional finding and suggests that CHM 
could be used as a general female fertility “tonic” for women trying to conceive 
even before they consider they may need conventional medicine assistance. 
This could be viewed as pre conception preparation for older women who want 
to conceive naturally if possible. 
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6.2 Pregnancy outcome and measurement parameter correlation 
Empirical experience of treating infertility with CHM in both China and the West has 
shown that most pregnancies result from CHM treatment in the first six menstrual cycles 
after treatment is started. The pregnancy rate after six cycles drops dramatically which 
suggests that CHM attains maximum effect in the first six menstrual cycles of treatment 
which is between 5-7 months post treatment commencement. However, this has yet to 
be confirmed by research and more pregnancies may be achieved if the treatment was 
extended for a longer period. Conversely with some patients the effects are seen well 
before that with pregnancies occurring from as early as one menstrual cycle of treatment 
which would suggest that the build up rate of medicinal effects varies between women. 
The pregnancy outcome rate in the treatment group of 34% is encouraging however one 
has to conclude that some percentage of the group of failed IVF patients treated would 
have achieved pregnancy naturally in any case and some percentage could also have 
been a result of the reduced stress (Kupka et al., 2003, p.190-195) resulting from being 
treated with CHM. 
 
What is more relevant is that if endometrial receptivity was only effected by the 
parameters measured in this study then from the statistically significant improvements 
one would have expected a much higher percentage of the treatment group to have 
become pregnant.  This begs the question “why was the pregnancy rate not higher”?, 
there are three possible explanations. Firstly, there are other factors involved in 
endometrial receptivity, one of these is well understood from the literature (immune 
system response – covered in section 2.7 of the literature review), but it seem that it is 
most likely there are other yet to be discovered physiological female and possibly male 
factors affecting endometrial receptivity. Secondly, it is possible that with further 
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treatment (more than three menstrual cycles) the six parameters we measured could be 
further improved and the pregnancy rate could also be further improved.  
 
This is unlikely to be the case because pregnancy rates seem to decrease after 6 
treatment cycles as has already been explained.  However, there has never been any 
research on pregnancy rates with long duration (more than 6 cycles) CHM treatment.  
Therefore more research would be needed to determine to what degree the parameters 
could be improved further and over what time period of treatment and if indeed any 
further improvements correlated with pregnancy rates. Thirdly, there is possibly an 
interrelationship between the parameters we have measured and immune response and 
also other unknown physiological factors yet to be discovered which may be the case and 
cannot be ruled out.  In any case 34% pregnancy outcome means that over 1/3 of the 
patients treated have achieved their desired pregnancy and given that no side effects 
manifest in any of the participants and the improvements in the parameters may possibly 
still result in some further pregnancies in the remaining 66% this would seem to be more 
than sufficient justification to promote the use of this treatment ethically for failed IVF 
patients. 
 
6.3 Results summary 
We set out to determine if CHM affected endometrial receptivity and if CHM changed 
any of the physiological factors effecting endometrial receptivity. The study was carried 
out in a scientific manner with the goal of providing evidence based results which would 
contribute to the body of knowledge regarding complementary medicine. The 
methodology choice of using two parallel studies, one with of a prospective, t study and 
one with a volunteer randomised placebo study proved to be a good decision as it 
allowed a comparison of the same endometrial receptivity measurements before and 
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after treatment in both groups. The randomised placebo control element in the reference 
group did strengthen the study credibility and also help in understanding why the degree 
of change was higher in the failed IVF treatment group compared to the healthy fertile 
reference group. It seems reasonable now to say that improved sub endometrial 
vascularity and endometrial thickness is one of the reasons CHM has been used to 
successfully treat infertility in the past. But, there are clearly other factors involved such 
as immune system response and likely, as yet undiscovered factors and the 
interrelationship between endometrial quality and immune system modulation of the 
endometrium opening up further areas of future research. This study has also provided 
valuable insight into other positive effects of CHM treatment of the infertile woman in 
terms of reduced FSH levels and raised progesterone levels. All this said, there are two 
significant main shortcoming of this study, firstly, we still do not know which herbal 
medicines are responsible for which physiological changes. This is an imponderable 
problem, as the very essence of TCM is that the medicines are a synergistic combination 
of individual medicinal substances and it is the active ingredients in the formula as a 
whole that deliver the therapeutic results.  Also the same condition in different patients 
has a different diagnosis and therefore a different herbal medicine formula. TCM 
advocates argue it is exactly this aspect that makes CHM so profoundly potent in difficult 
cases such as unexplained infertility. Secondly, for ethical and practical recruiting reasons 
it was not possible to double blind and randomise the treatment group, which would 
have provided even more credible results from the point of view of scientific acceptance 
of papers published from this study.  
 
There were no reported side effects of the herbal medicines at all in any of the 100 study 
participants. This is an important additional finding as conventional assisted conception 
treatment hormone treatment to stimulate ovarian follicle production side effects can be 
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quite unpleasant. Another benefit from herbal infertility treatment of the kind used in 
this study is that no breaks between treatment cycles are needed. Treatment can 
continue back to back for as long as is needed to achieve a pregnancy. Traditional 
assisted conception treatment with stimulation hormones requires at least a one cycle 
break after a failed cycle for recovery before a subsequent treatment cycle can 
commence. Considering all these aspects, compared to conventional assisted conception 
treatment, CHM offers a viable alternative, particularly if the patient is concerned about 
side effects of fertility drugs or wishes to take a natural approach to her fertility 
treatment. 
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C h a p t e r  V I I  
CONCLUSIONS AND RECOMMENDATIONS 
 
 
7.1 Conclusions 
There will be no surprise in the results of this study for the TCM community, or indeed 
the failed IVF patients who have already been successfully treated with CHM. Empirically 
and experientially, within the TCM profession it is well accepted that CHM treats 
unexplained infertility with a high degree of success. For those outside the profession 
(conventional medicine fertility clinicians and the public in general) lack of understanding 
regarding TCM methods, effectiveness and safety is common. The contribution of this 
study is to provide one piece of scientific evidence based research which can hopefully 
help to change this perception and also give the TCM practitioners scientific support their 
treatment of female infertility. 
 
7.1.1 Study contribution 
The study demonstrated that within the treatment group of 50 failed IVF 
patient previously diagnosed with unexplained infertility CHM does indeed 
improve all the 6 physiological parameters known to affect endometrial 
receptivity by a statistically significant amount when comparing measurements 
before and after treatment, however there were no controls in this group. The 
study also demonstrated that the same physiological parameters improved to a 
lesser extent, but still statistically significant in normal healthy non-pathological 
volunteers with the same inclusion and exclusion criteria who were double 
blinded and randomised into treatment and placebo arms.  The placebo arm 
showed no significant change in the same parameters. This study also 
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demonstrated a 34% pregnancy rate in the failed IVF treatment group over the 
3 menstrual cycles following treatment (6 menstrual cycles in total). It appears 
that CHM is effective at improving endometrial receptivity in failed IVF patients. 
However, although pregnancy rates were encouraging, these could be the result 
of either treatment or placebo effects possibly resulting in reduced stress levels. 
The main question resulting from this work is, what else does this mean, could 
the same treatment approach used with failed IVF patients help infertile 
couples achieve a pregnancy before they are committed to IVF and other 
treatment?.  Given that the non-pathological group of volunteers also showed 
increased endometrial receptivity in addition to the failed IVF patient group, it is 
reasonable to deduce that endometrial receptivity in a group of sub fertile pre 
IVF infertile females would also be improved and therefore pregnancy outcome 
would also be improved. Taking this logical analysis one stage further, if females 
who were not conceiving in the accepted time to conceive for normal fertile 
couples (18 -24 months) were treated with CHM what percentage would never 
need undergo conventional medicine investigations or need ART? 
Understanding this from a scientific point of view would of course require 
similar investigative study but with a pre IVF infertile sample group and a 
delayed conception sample group ideally double blinded RCT studies. This 
should be possible as it is much more likely to find volunteers for a placebo 
study in these two groups as they are not at the end of the fertility treatment 
road, to the contrary they are just starting the journey. 
 
7.1.2 Ambiguous conclusions 
Unfortunately for reasons discussed in the methodology chapter of this 
manuscript we were not able to carry out a double blinded RCT on the failed IVF 
  104 
 
treatment group. It is possible that the improvements demonstrated in 
endometrial receptivity in 50 patients could have been from placebo effect 
alone which is unable to be disproven in this group alone. Although it was not 
possible to include a control untreated or placebo treated arm in the treatment 
group this was desired and a major weakness of the Treatment group part of 
this study. A clear distinction is still lacking between the relative value of placebo 
and untreated control groups as well as between perceived and true placebo 
effects. The resulting true placebo response is highly variable and  complex 
boundary conditions exist which determine the true placebo effect. The best 
way to deal with this would be the inclusion of an untreated control group in 
addition to a placebo group provided that there are no ethical objections (Ernst 
& Resch, 1995, p.551-553). 
 
This situation was anticipated when it became clear that an RCT on the 
treatment group would not be possible in this study and led to the decision to 
include an additional parallel separate double blinded RCT study group of 
healthy volunteers. The treatment arm of the reference group also showed an 
improvement in endometrial receptivity and yet the placebo arm showed no 
statistically significant improvement at all.  When drawing conclusions about the 
placebo effect on the failed IVF treatment group readers should also to take 
into account the positive outcome of the double blinded RCT reference group 
before drawing overall conclusions about this study.  
 
7.1.3 Unexpected outcomes 
Some degree of improvement was expected as it was previously known from 
experience that CHM improved pregnancy rates in failed IVF patients. However, 
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the degree of improvement in the failed IVF treatment group was unexpected, 
all six measurement parameters achieved a P value of <0.001 which shows 
marked improvements. It was logical to expect that the reference group would 
also show some effects from CHM, but because there no previous data existed 
on normal healthy women there was no expectation on what, if any 
improvements would be found. 
 
7.1.4 Improvements in hindsight 
With the benefit of hindsight it may have been possible to recruit a sample 
group for a placebo based RCT from the waiting lists of IVF clinics, although it is 
by no means clear they would be happy to participate in a 3 month long study. 
The difference in this sample group would be none would have elected to be 
treated with CHM be the very fact they are on a waiting list for IVF treatment 
and this could effect their compliance and commitment to any study then enter.  
The literature search was fundamental to structuring of the study and the 
conventional medicine research regarding previously, proven measurements of 
endometrial receptivity resulting in defining the most appropriate 
measurement parameters to be used in the study. Previous workers had already 
lent significant creditability to which parameters would be most appropriate in 
researching CHM effects on endometrial receptivity (Raine-Fenning et al., 2004, 
p.2605-2614). These formed the foundation of the study measurement system 
used in the methodology. Given the ethical issues surrounding an RCT in 
infertility treatment, the decision to establish a reference for normal healthy 
women and to research two parallel groups has proven to be a good decision. 
The failed IVF treatment group still provided a sound scientific study which 
tested the hypothesis with the volunteer RCT group supporting the findings in 
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the failed IVF treatment group.  The next step in investigating this subject 
further would be to recruit a group of women actively trying to conceive and 
having difficulty after a normal length of time (2 years) and then double blinding 
and randomising this group and measuring the pregnancy outcome between 
treatment arm and placebo arm. 
 
7.2 Recommendations 
The author of this thesis recommends that the study findings be used in three ways. 
Firstly contribute to the body of evidence regarding CHM safety and efficacy. Secondly, to 
initiate more cooperation between the conventional medicine ART community and the 
TCM infertility community with a view to improving cooperation and integration leading 
to overall assisted conception success rates and reduction of side effects and reduction in 
patient costs. Thirdly, as a springboard for other researchers who wish to further study 
the effects of CHM on endometrial receptivity.  
 
The next steps in continuing this research work would be: 
1) A longer term study to investigate if further improvements in endometrial 
receptivity or pregnancy rate outcome could be achieved with longer 
treatment periods. 
 
2) A repeat study on failed IVF patients but with a control arm, possibly from 
IVF waiting lists which may allow for a RCT based study to be carried out on a 
treatment group. 
 
3) Further research into why sub endometrial flow did not significantly increase 
in normal healthy women yet it did in the pathological women. 
 
4) A RCT study into the effects of CHM on the immunological changes and 
moderation of natural killer cells in endometrial tissue at implantation stage 
of the menstrual cycle. 
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7.2.1 Publishing 
The findings of this study will produce at least one paper which will be 
submitted to a leading peer reviewed conventional reproductive medicine 
journal such as Fertility and Sterility or Human Reproduction. This would allow 
the findings to have a positive influence on how the conventional medicine 
fertility community views TCM and CHM. The study findings will also be 
presented at international fertility conferences and ultrasound conferences, 
such as BMUS, ISOUG, COGI, ESHRE and ISNAR.  The abstract has already been 
accepted for presentation at the 11th COGI conference in Paris in November 
2008. 
Another similar paper will also be submitted to a major Western TCM journal, 
such as European Journal of Oriental Medicine (EJOM) or The Journal of Chinese 
Medicine (JCM) and will delivered at the worldwide TCM congress in 
Rothenberg, Germany in 2009. This will allow the TCM community to see that 
research is an important part of practicing TCM in today’s Western world and 
encourage others to carry out similar research within their chosen areas of 
specialisation.  
7.2.2 Maximising the value of this study findings 
The lack of respect for each others work between the TCM and conventional 
medicine community is an unfortunate reality in the West today. Both seem to 
doubt the validity of each others work without really taking the time to 
understand the merits of each. This author believes that the future will 
eventually be in integrated medicine as the benefits of combining each 
approach to medicine become clear to the public and accepted by each medical 
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discipline. It is most likely that with the internet and a more informed, curious 
and demanding public that this is where the drive will come from for an 
integrated medical system of care. The benefits of an integrated approach are 
most importantly, higher success rates in infertility treatment, reduced side 
effects and lower stimulation from pharmaceutical hormones and lower costs 
to the patients. This study indicated that the combination of both conventional 
and CHM could give higher overall success rates than either can achieve 
standalone. There could potentially, also be huge benefits to the NHS as the 
expensive drugs used in ART could be reduced or replaced with CHM and 
natural cycle IVF leading to significantly reduced costs within the NHS. It would 
make sense therefore to take two approaches to forwarding the foundations 
laid by this study. Firstly, seek out naturally orientated conventional medicine 
fertility experts who would be open to reacting on the results from this study. 
Secondly, target the segment of the general pubic suffering from infertility and 
promote to them directly the positive effects of using CHM either before ART or 
alongside ART, effectively promoting an integrated medicine approach to 
treating their infertility. This would have the result of driving demand at the GP 
community level as well as conventional infertility clinics for integrated 
infertility treatment. 
 
7.2.3 Further research 
This study has produced some statistically significant findings, certainly 
substantial enough to justify both deeper and wider research into the 
effectiveness and safety of CHM treatment of infertility and recurrent 
miscarriage. The three most interesting related subject areas for new research 
studies would be:  
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1) Endometrial receptivity in sub fertile females who have not yet engaged 
in conventional medicine treatment. 
 
2) Sub fertile patients diagnosed with reduced ovarian function. 
 
3) Patients suffering recurrent early miscarriage.  
 
7.2.3 Change of practice 
There is no real change in practice for the TCM fertility specialist community. 
They are already treating patients in exactly the same manner investigated in 
this research study on a daily basis in the UK. This study did not highlight any 
anomalies or deficiencies in the TCM treatment protocol, there were no side 
effects reported, in fact in general patients felt much better on CHM than 
previously. The published papers resulting from this study will lend credence to 
their work in the eyes of their patients. The real desired change in practice must 
be focused on the conventional medicine fertility clinicians who should be 
encouraged in the light of this work to investigate integrating CHM into their 
practice and in so doing provide a better service to their patients. If adopting 
CHM as a complementary treatment alongside conventional assisted 
conception treatment achieves higher success rates and reduced side effects 
without any downside maybe one or two fertility clinics could be persuaded to 
run a combined trial with patients going through conventional IVF.  
  
  110 
 
C h a p t e r  V I I I  
REFLECTIONS ON PROFESSIONAL DOCTORATE  
 
 
8.1 Reflection on learning  
(Schon, 1983) suggested that the capacity to reflect on action so as to engage in a 
process of continuous learning was one of the defining characteristics of professional 
practice. He argued that the model of professional training which he termed "Technical 
Rationality"of charging students up with knowledge in training schools so that they 
could discharge when they entered the world of practice, perhaps more aptly termed a 
"battery" model has never been a particularly good description of how professionals 
"think in action", and is quite inappropriate to practice in a fast-changing world.  
 
The quality and depth of the reflection, however, is not specified within this formulation: 
and it is interesting those two different traditions of professional development emphasis 
seemingly contradictory aspects. (Reynolds, 1965) and particularly (Dreyfus & Dreyfus, 
1986) discuss how developing practitioners come gradually to take for granted aspects of 
their practice which initially preoccupied them, and move on to be concerned about 
(reflect upon) wider matters. This taking-for-granted on the one hand, and reflection on 
the other, offers a view of how reflection-on-action deepens in the course of a career. 
Schon’s great contribution was to bring ‘reflection’ into the centre of an understanding of 
what professionals do. The Reflective Practitioner (1983) is directed against ‘technical-
rationality’ as the grounding of professional knowledge.  It is this work that resonates with 
my personal style and a guiding framework for how I conduct myself in my professional 
life. 
  111 
 
8.2 Vocational life goals 
My own vocational life goals are the driving force behind why I embarked on the 
professional doctorate programme. Even before acceptance on to study for a 
professional doctorate I wanted to be able to complete a piece of research to the highest 
academic and scientific standards and be able to publish this as work at a standard 
beyond my MSc research work. I believed (and still believe) that doctorate level research 
was the best way to achieve the second my vocational life goals below the first would 
also be improved to some degree by the discipline in completion the professional 
doctorate and this has proven to be the case. 
Continual improvement in healing success rates 
Publicising evidence based proof of efficacy and safety of natural medicine 
 
8.3 Critical reflection learning during the professional doctorate course 
The following reflection on positive learning experiences experienced during my 
professional doctorate programme are organised by the learning outcomes for the 
University of Portsmouth Professional Doctorate course. 
Part 1 – taught modules learning outcomes 
On refection the taught modules have developed my basic skills in research, notably, my 
statistical skills and research methodology skills. I now feel that I can confidently apply 
myself to any research problem and know how to complete a study to the accepted UK 
academic and scientific standards. I was not able to do this before completing the part 1 
taught modules of this course. 
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Part 2 – research module reflection 
The following statements in bold are the learning outcomes for the unit followed by 
reflections on my own learning and personal development. 
 
1) Conduct ethical research in a complex, multidisciplinary environment 
  
The difference between master’s level research and doctorate level research at first is 
difficult to comprehend. It was not until I started to develop the methodology for my 
study that I appreciated how much more complex doctorate level research is in reality. 
The challenges of designing a study that weaved a route round the limitations 
conditional on ethics approval and patient recruitment was mentally extremely 
challenging and proved very difficult to come to terms with. I was determined to find a 
way to design a study that was scientifically sound and also achievable. The resulting 
study was not as I would have desired and I always felt it was a compromised study, but 
never the less one that needed to be completed to contribute to the body of knowledge 
and evidence on the safety and effectiveness of CHM. I hope others who follow me on 
this journey have an easier time because of the foundation set but this study. 
 
2) Attain command of the latest knowledge and understanding of appropriate to 
their area of professional or educational practice 
 
In the course of reading the literature on each aspect of this study I was able to read 
both deep and wide, from CHM to 3D ultrasound, from pharmacology to gynaecology, 
from physiology to immunology. It was a real challenge to cover each subject area 
(ultrasound, conventional reproductive medicine, TCM reproductive medicine and 
CHM) to the depth needed in each subject area and still working within the word limit 
for the this dissertation. This was much more demanding that I expected and took much 
more time than I expected. On reflection I feel I should have approached this 
differently, starting with a mind map of everything I needed to cover in the literature 
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review and structuring the time allocated to each and producing a timeline for the 
entire literature review. However, with that reflective experience, I now feel that I could 
address myself to any literature review and be able to gauge the amount of work and 
the complexity of the work needed.  
 
3) Demonstrate independent critical judgment of complex issues and situations 
 
The complexity of the situation regarding ethics approval for a CHM study and the 
ethical issues related to withholding treatment from a demanding treatment group 
challenged my critical judgement. This was indeed a complex issue to grapple with. 
Extracting a meaningful study from this situation needed a fresh approach and the 
deliberations led me to the concept of a RCT reference group and a non-randomised 
treatment group. On reflection I feel this was exactly the right approach given we could 
not randomise the treatment group. In fact on reflection we learned some things that 
would have been missed in a treatment only group study. We now have reference 
levels of endometrial receptivity in healthy women and also we know that CHM does in 
fact also enhance the fertility of normal women. 
 
4) Make a significant and original contribution to professional or educational 
practice 
 
This is my major area of contribution with this study. On reflection, this is exactly what I 
set out to achieve and indeed the entire reason I embarked on the professional doctorate 
program. Going back to my second vocational life goal “Publicising evidence based proof 
of efficacy and safety of natural medicine”, I have achieved this goal with the professional 
doctorate program and this clinical research study.  The significance of publishing original 
work that has never been done before by applying scientific evidence based research 
using state of the art 3D Doppler ultrasound and serum blood measurements to 
traditional herbal medicine treatment cannot be underestimated.  The contribution made 
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by this study to the TCM profession in the Western world is extremely important as it lays 
one more foundation stone on which the body of evidence for safety and efficacy of 
herbal medicine and hopefully will encourage other researchers to follow with many 
more evidence based studies. On reflection I feel I have fulfilled my original reason for 
setting out on the path and become a much more accomplished researcher and stronger 
practitioner. 
5) Challenge current thinking and provide authoritative solutions to practical and 
research problems 
 
There can be no doubt that this work challenges current thinking by providing 
authoritative results. The current thinking among the public and many practitioners of 
conventional medicine is that CHM is dangerous and ineffective.  However this is based 
more on ignorance and absence of data that being the fact. This study demonstrates in 
scientific terms this not to be the case in the hands of qualified, registered practitioners. 
On reflection this study does not make any contribution to the government movement 
to regulate CHM , however the house of lords select committee are addressing this 
issue and a copy of the final manuscript will be sent to the chairman of this committee 
and the minister for health to forward the cause of protecting the public with a 
controlled herbal medicine pharmacopeia only available to licensed practitioners. 
 
6) Manage and make effective use of the appropriate physical, financial and human 
resources 
 
This study was extremely difficult to fund as the main source of funds for medicine 
research in the UK is from pharmaceutical companies and these are not interested in 
funding natural herbal medicine studies as they view this as competition to the sale of 
the drugs they produce and sell. Indeed, as mentioned earlier, I was actively 
discouraged from completing this work by a major pharmaceutical company. The other 
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source of funds is health related charities and although several were approached, the 
effort and time expended was way out of scale with the few thousands of pounds on 
offer. Therefore, this study had to be funded and resourced by this author which was a 
challenge and on reflection maybe more could have and should have been done to 
search for alternative funding. I hope that the completion of this study and publishing 
of results will make funding easier in the future. 
 
7) Using a variety of formats, disseminate their theoretical, research and 
professional understanding to critical communities 
 
The results of this work will be disseminated in several ways to the critical communities. 
The abstract of this research has recently been accepted for presentation at the “The 
11th World Congress on Controversies in Obstetrics, Gynecology & Infertility” (COGI) 
held in Paris in November 27-30, 2008 which will start the dissemination of this work to 
the conventional reproductive medicine community. The same abstract has also been 
accepted for presentation at “The 40th worldwide TCM conference” held in Rothenberg 
Germany, May 19-24, 2009 which will start the dissemination to the TCM community. In 
addition several papers will be published from this research in both peer reviewed TCM 
journals and peer reviewed conventional reproductive medicine journals in 2009. In 
addition abstracts of the work will be available on the RCHM website for download to 
coincide with the presentation at COGI on 30th November 2008. 
 
8) Reflect on learning achieved within a framework of advanced professional 
practice 
 
I can say without any hesitation that the learning I achieved personally will help me to 
become both,  a more competent researcher and a more advanced practitioner.  
Without doubt the depth of my knowledge has increased significantly as has the depth 
of understanding of how to approach research has improved immensely. The old saying 
that “you don’t know what you don’t know” definitely applied to me when I embarked 
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on this professional doctorate. On reflection I thought I was equipped to complete 
doctorate level research and in the area of statistics and research methodology this was 
in hindsight not the case at all. There is a clear step up between master’s level research 
and doctorate level research which I could not have made without the taught modules 
provided in the professional doctorate program.  On reflection I am glad that Dr 
Graham Mills gentley guided my decision towards professional doctorate and away 
from a PhD. I think it would have taken me much longer and with much harder work to 
accomplish what I have accomplished on a PhD pathway compared to professional 
doctorate pathway. 
 
9) Influence and provide inspiration and leadership for others in a changing 
environment of healthcare education or professional practice. 
This part of reflecting on the course resonates with me more than any other aspect by far. 
Many practitioners in the TCM profession stop studying when they are awarded their BSc 
in TCM with only a handful of practitioners going on to complete MSc’s and publishing 
research. I supervise on the MSc in Oriental Medicine at LCTA in London and each year I 
help a few students from all over the world to complete their master’s thesis and publish 
the results. I also write regularly in the RCHM and BAcC newsletters promoting the need 
for more evidence based research and encouraging members to consider completing an 
MSc and publishing. I passionately believe that the only way that complimentary 
medicine of any discipline will become accepted by conventional medicine and the public 
as truly worthy of integration with conventional medicine is through 1000’s of evidence 
based studies such as this one. 
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8.4 Summary 
In summary, my vocational life goal is to improve healing success rates and publicise 
evidence based research into natural medicine. Reflection on my time in the professional 
doctorate programme I can say without hesitation I have moved a long way down the 
road on both these goals compared when I started the course almost 5 years ago. Much 
has already been achieved during the professional doctorate program for my personally, 
but MUCH more still to be done. I plan to focus the next phase of my learning on further 
improving healing success rates by a combination of learning new treatment methods 
(such as medical ozone therapy) and carrying out and publicising more research myself . I 
have a new research study defined which will be completed jointly with a conventional 
medicine consultant gynaecologist and reproductive medicine specialist and will 
investigate the comparison of conventional IVF drugs with CHM to improve ovarian 
response to stimulation in IVF cycles and should start in early 2009.  
My sincere thanks go to all those who have helped me, supported me and taught me at 
the University of Portsmouth during my time on the professional doctorate programme 
Thank you all! 
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From: Ouseley, Katherine [Katherine.Ouseley@Camdenpct.nhs.uk] 
Sent: 24 April 2006 12:30 
To: 'Trevor@naturalgynae.com' 
Subject: RE: Enquiry 
Dear Trevor, 
  
You are very welcome. Best wishes with the development of your project on behalf of this Committee. 
  
Kind regards, 
Katherine Ouseley 
  
-----Original Message----- 
From: Trevor Wing [mailto:Trevor@naturalgynae.com] 
Sent: 24 April 2006 12:15 
To: 'Ouseley, Katherine' 
Subject: RE: Enquiry 
Dear Katherine,  
  
Thank you for your prompt reply. This is exactly what I needed and suspected was the case. I have forwarded your 
reply to the Dean of the Biomedicine faculty at Portsmouth university to request a university ethics review of the 
proposed study.  
  
Thank you again.  
Kind regards 
Trevor Wing 
  
 
From: Ouseley, Katherine [mailto:Katherine.Ouseley@Camdenpct.nhs.uk]  
Sent: Monday, April 24, 2006 11:40 AM 
To: 'Trevor@naturalgynae.com' 
Subject: RE: Enquiry 
Dear Mr Wing, 
  
Please accept my apologies for the delay in getting back to you.  
  
Your enquiry was forwarded on to the Chair for advice. As discussed, it is not essential that this project is reviewed by an 
Ethics Committee as the research site is non-NHS. However it is strongly recommended that due to the fact this project is 
part of a degree, this research project should be reviewed by the Ethics Committee at your University. 
  
Should you have any further queries, myself and the Chair will be more than happy to assist.  
  
Kind regards, 
Katherine Ouseley  
Research Ethics Co-odinator  
Camden & Islington Community Local Research Ethics Committee  
Room 3/14  
3rd Floor, West Wing  
St Pancras Hospital  
4 St Pancras Way  
London, NW1 0PE  
Tel: 020 7530 3799  
Fax: 020 7530 3931  
E-mail: katherine.ouseley@camdenpct.nhs.uk  
Website: www.corec.org.uk  
DISCLAIMER:  
This e-mail and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken 
in respect of this e-mail is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then 
permanently delete what you have received. 
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-----Original Message----- 
From: Trevor Wing [mailto:Trevor@naturalgynae.com] 
Sent: 13 April 2006 08:48 
To: katherine.ouseley@camdenpct.nhs.uk 
Subject: Enquiry 
 
Dear Ms Ellis,  
I am emailing you in your capacity as chair or our Local REC committee. I would appreciate your advice as I am not 
sure how to proceed with my research. I am completing a professional doctorate research study at my private 
complimentary medicine practice in Harley Street. I have attached a copy of the research proposal for you to read. My 
question is because this study is a private practice study outside the NHS does it need LREC or COREC approval?.  
I appreciate your time is very valuable and thank you for your help  
Yours sincerely  
Trevor A. Wing  
*************************************************************************** This e-mail is confidential and privileged. If you 
are not the intended recipient please accept our apologies; please do not disclose, copy or distribute 
information in this e-mail or take any action in reliance on its contents: to do so is strictly prohibited and may 
be unlawful. Please inform us that this message has gone astray before deleting it. Thank you for your co-
operation. *************************************************************************** 
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APPENDIX C 
MSc Pilot Study Results 
 
Variable Age 35 
Mean difference 
(SD) 
Age >35 
Mean difference 
(SD) 
P-value 
Endometrium pre-ovulatory 
(mm) 
(*)
 
-0.4 (-1.6, 1.5) 0.0 (-0.5, 0.4) 0.12 
FSH -1.7 (2.6) -1.7 (2.9) 0.96 
R Ov follicles 0.8 (1.8) 0.6 (1.9) 0.71 
L Ov follicles 0.2 (2.1) 0.5 (2.8) 0.64 
Total follicles 1.0 (3.2) 1.1 (4.2) 0.89 
Graafian size in mm 4.4 (6.4) 1.6 (4.3) 0.07 
  
Variable Age 35 
Mean difference 
(SD) 
Age >35 
Mean difference 
(SD) 
P-value 
Endometrium post-ovulatory 
(mm) 
2.3 (4.3) 1.6 (3.7) 0.52 
UA PS 
(*)
 6.0 (2.5, 11.0) 6.5 (1.0, 8.8) 0.63 
UA PI 
(*)
 -0.9 (-2.9, -0.3) -1.3 (-3.2, -0.5) 0.39 
Progesterone 
(*)
 11.2 (4.6, 23.4) 4.9 (1.6, 14.3)  0.07 
CL Size 2.6 (4.9) 1.8 (3.6) 0.57 
CL vascularity 
(*)
 1 (0, 1) 1 (0, 1) 0.43 
    
(*) Median (IQ range) reported for each group. Analysis using Mann-Whitney test 
Table 3  
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APPENDIX E 
Pharmacy Details and Medicine Container Labelling 
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Chinese Herbal Dispensary 
Unit 53A,  
Nutwood Trading Estate,  
Limestone Cottage Lane, 
Sheffield. 
S6 1NJ 
Tel: +44 (0)114-2330888  
Email: info@4chineseherbs.co.uk 
Web: www.4chineseherbs.co.uk 
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APPENDIX F 
Ultrasound Machine Specifications 
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APPENDIX G 
Standardised Power Doppler Settings 
Study ultrasound machine  
GE Voluson E8 
Transducer RIC6-12 
System software version 6.2.2.1395 
 
2D PD settings 
 
Pwr 87% 
Gn 8 
SRI II 4 
Frq mid 
Qual norm 
WMF mid1 
PRF 0.6 Khz 
 
3D static PD settings 
 
Th33/Qual mid2 
B120º/V50º 
Mix 6/94 
SRI II 4 
  154 
 
APPENDIX H 
Study Raw Data 
 
VOCAL Settings =  9 degrees, 180 degree sweep, 5mm outside shell
ENDOMETRIAL RECEPTIVITY STUDY DATA SET  (Treatment group A)
PRE-TREATMENT (7 days post ovulation) POST-TREATMENT (7 days post ovulation)
Patient Group Age
IVF 
cycles
T/P ET SE VI SE FI SE VFI FSH PROG ET SE VI SE FI SE VFI FSH PROG Pregnant
1 8500 TG 45 3 T 8.9 2.1 37.2 0.9 9.8 32 11.1 2.2 37.4 1.0 8.1 42 Y
2 8501 TG 43 5 T 7.2 1.9 36.1 0.7 8.5 29 10.3 1.9 36.5 0.8 7.3 34
3 8502 TG 38 2 T 5.0 2.3 37.4 1.0 10.3 78 10.6 2.5 38.4 1.3 9.2 72 Y
4 8503 TG 39 5 T 5.7 2.0 37.0 0.9 11.0 34 8.1 2.1 37.4 1.1 10.3 39
5 8504 TG 41 4 T 11.7 1.9 36.6 0.8 5.6 29 12.9 2.0 37.1 0.9 4.2 35
6 8505 TG 42 6 T 8.1 1.8 36.3 0.8 11.0 35 9.6 2.0 37.1 1.2 8.9 42
7 8506 TG 39 8 T 7.0 2.2 37.6 1.0 8.1 23 9.0 2.4 37.9 1.2 7.4 33
8 8507 TG 42 4 T 7.8 2.3 37.8 1.1 10.0 43 8.9 2.5 38.3 1.3 8.9 51 Y
9 8508 TG 40 5 T 5.0 2.4 38.0 1.3 8.7 35 9.1 2.4 38.0 1.4 8.1 43
10 8509 TG 43 6 T 16.2 1.9 36.3 0.8 5.6 62 15.9 2.1 37.0 1.0 5.1 61
11 8510 TG 37 4 T 8.3 1.8 35.9 0.7 7.8 44 10.1 1.8 36.0 0.8 5.2 56
12 8511 TG 41 3 T 7.1 2.3 37.6 1.0 9.5 51 8.9 2.5 38.4 1.3 8.1 52
13 8512 TG 39 5 T 9.6 2.0 36.9 0.9 8.6 36 11.0 2.0 36.7 0.8 7.5 45 Y
14 8513 TG 44 6 T 5.3 2.3 37.7 1.2 7.7 23 7.0 2.5 38.5 1.4 7.2 36 Y
15 8514 TG 42 7 T 8.3 1.7 35.8 0.7 4.3 43 9.4 1.8 35.9 0.8 4.6 67
16 8515 TG 45 4 T 7.8 1.8 36.0 0.8 12.1 26 8.9 1.8 36.1 0.8 10.3 39
17 8516 TG 44 8 T 9.7 2.7 38.5 1.5 6.3 47 11.2 2.8 38.8 1.7 6.2 51
18 8517 TG 45 3 T 6.9 2.4 37.9 1.3 12.1 27 8.1 2.5 38.0 1.4 11.3 38
19 8518 TG 41 2 T 10.2 1.9 36.1 0.8 4.6 44 11.8 2.2 36.8 1.0 4.7 49 Y
20 8519 TG 45 3 T 4.4 1.8 36.0 0.8 14.0 23 6.7 1.9 36.3 0.9 12.9 28
21 8520 TG 42 4 T 8.7 1.8 35.9 0.7 5.6 45 9.2 1.8 36.0 0.8 5.4 47 Y
22 8521 TG 44 5 T 5.6 1.7 36.1 0.6 8.9 34 8.4 1.9 37.5 0.9 7.7 46 Y
23 8522 TG 39 7 T 9.7 2.2 38.1 1.3 6.7 38 10.7 2.2 38.3 1.5 5.9 42
24 8523 TG 46 5 T 7.2 1.7 35.3 0.5 14.2 23 7.6 1.8 35.6 0.6 14.0 25
25 8524 TG 42 4 T 8.8 1.8 36.6 0.8 8.9 39 9.3 2.0 37.5 1.1 6.7 46 Y
26 8525 TG 44 7 T 5.4 1.6 35.4 0.6 13.2 27 7.2 1.8 36.1 0.7 10.9 32
27 8526 TG 43 5 T 8.9 2.1 37.1 1.0 9.2 36 10.2 2.2 37.6 0.9 8.2 42
28 8527 TG 45 4 T 13.1 2.2 37.4 1.2 5.6 47 12.9 2.2 37.5 1.1 5.4 52 Y
29 8528 TG 46 1 T 8.6 1.9 36.9 0.8 9.9 30 9.0 2.0 37.2 0.8 8.1 34
30 8529 TG 43 6 T 6.8 1.9 36.3 0.7 10.2 41 7.0 1.9 36.2 0.8 10.0 40
31 8530 TG 41 2 T 9.1 1.8 36.2 0.4 8.9 45 10.1 2.0 37.6 0.8 8.4 46 Y
32 8531 TG 40 7 T 6.3 1.7 35.6 0.5 7.7 32 7.5 1.9 37.0 1.0 6.4 34
33 8532 TG 44 4 T 7.9 1.8 36.3 0.9 11.8 29 8.0 1.9 37.5 1.1 10.9 30
34 8533 TG 38 2 T 10.0 2.4 38.1 1.2 7.7 42 11.2 2.4 38.3 1.3 7.0 40 Y
35 8534 TG 44 5 T 6.9 1.7 35.5 0.7 12.1 28 6.5 1.8 36.1 0.8 13.8 25
36 8535 TG 38 3 T 11.0 2.3 37.9 1.0 8.5 39 11.5 2.3 38.1 1.2 7.8 46 Y
37 8536 TG 39 2 T 8.3 1.8 36.3 0.6 9.1 32 9.1 2.0 37.3 0.8 9.3 31
38 8537 TG 35 3 T 10.2 2.1 37.5 1.1 7.9 45 10.3 2.3 37.9 1.4 6.3 45 Y
39 8538 TG 45 6 T 4.5 1.5 35.1 0.4 16.8 26 4.0 1.5 35.8 0.5 17.2 23
40 8539 TG 38 4 T 6.8 1.8 35.9 0.4 9.2 34 7.9 2.1 37.2 1.0 8.4 39
41 8540 TG 41 2 T 8.4 1.9 36.6 0.9 10.1 29 8.8 2.1 37.8 1.1 9.8 35 Y
42 8541 TG 43 4 T 12.3 2.3 38.3 1.5 11.1 37 13.4 2.4 38.6 1.6 11.6 41 Y
43 8542 TG 43 4 T 7.8 1.9 37.1 0.8 10.2 29 7.8 2.0 37.4 0.8 11.0 27
44 8543 TG 45 5 T 3.4 1.6 36.0 0.5 19.8 18 3.0 1.6 35.9 0.5 18.8 20 Y
45 8544 TG 41 3 T 11.3 2.0 37.8 1.1 9.1 42 12.4 2.6 38.5 1.4 8.0 46
46 8545 TG 32 5 T 8.9 1.8 36.9 0.8 7.9 35 9.6 2.1 38.9 1.2 6.2 54 Y
47 8546 TG 39 2 T 6.2 1.6 35.1 0.4 13.3 29 7.6 1.8 36.6 0.9 8.5 39
48 8547 TG 37 4 T 13.1 2.2 38.3 1.4 10.3 52 13.2 2.4 39.0 1.6 7.8 56
49 8548 TG 34 3 T 5.6 1.8 37.4 1.0 7.8 46 8.5 2.0 38.5 1.3 6.7 43
50 8549 TG 45 7 T 9.4 1.7 36.1 0.8 15.9 30 8.7 1.6 36.2 0.8 16.0 28
ENDOMETRIAL RECEPTIVITY STUDY DATA SET (Reference  group B  (P= placebo and T=treatment)
1 9500 VG 21 P 13.1 3.1 32.1 1.4 6.3 56 12.8 3.4 32.4 1.5 6.8 54
2 9501 VG 24 T 9.3 2.9 23.1 1.3 5.5 34 11.0 3.1 27.4 1.3 3.6 43
3 9502 VG 21 P 10.5 3.3 36.8 1.5 6.7 65 9.0 3.6 35.9 1.6 7.1 67
4 9503 VG 26 P 8.5 3.2 36.5 1.4 7.1 56 8.0 3.3 37.0 1.5 7.6 57
5 9504 VG 27 P 11.7 3.4 34.4 1.5 8.0 43 11.0 3.8 38.4 1.7 6.7 44
6 9505 VG 32 T 8.3 3.7 37.2 1.4 4.3 47 10.0 3.8 39.1 1.5 4.7 55
7 9506 VG 31 T 9.9 3.8 36.4 1.3 4.8 68 10.0 3.7 25.6 1.0 4.3 54
8 9507 VG 29 T 6.4 2.5 35.1 1.6 6.7 45 9.0 2.9 38.0 1.8 6.0 43
9 9508 VG 25 P 13.6 2.7 38.5 1.4 7.2 32 13.0 2.7 37.1 1.1 7.8 36
10 9509 VG 34 T 5.6 2.0 37.4 1.5 5.4 46 7.0 2.5 38.6 1.7 6.9 43
11 9510 VG 32 T 7.1 3.6 36.3 1.3 6.7 36 9.0 3.7 37.1 1.5 6.8 36
12 9511 VG 33 P 7.8 3.1 37.7 1.2 8.4 43 8.0 3.3 38.1 1.3 8.0 48
13 9512 VG 32 T 6.3 2.9 38.4 1.3 9.0 29 7.0 2.7 37.8 1.3 7.5 48
14 9513 VG 29 P 8.3 2.6 37.9 1.7 6.7 38 8.0 2.7 38.1 1.8 6.9 42
15 9514 VG 28 P 9.9 3.3 38.5 1.5 4.8 43 9.0 3.2 38.1 1.4 5.5 39
16 9515 VG 24 T 10.7 2.5 36.1 1.4 7.8 29 13.0 2.9 38.6 1.6 7.1 28
17 9516 VG 30 T 11.3 3.3 37.5 1.6 9.2 57 13.0 3.4 38.9 1.8 8.7 63
18 9517 VG 25 P 10.6 2.8 36.1 1.5 4.8 49 11.0 3.1 37.6 1.7 4.7 56
19 9518 VG 23 P 13.5 2.7 37.3 1.1 3.1 59 13.3 2.5 36.9 1.3 3.2 56
20 9519 VG 26 T 10.9 3.2 37.6 1.4 4.0 63 12.2 3.4 37.9 1.6 3.6 67
21 9520 VG 32 P 8.2 2.9 38.0 1.2 5.1 50 8.3 2.9 37.8 1.2 5.3 52
22 9521 VG 34 T 11.4 3.1 38.5 1.4 4.1 53 12.5 3.2 38.7 1.6 4.0 53
23 9522 VG 21 P 13.4 3.5 38.7 1.6 2.4 67 13.2 3.5 38.8 1.6 3.0 66
24 9523 VG 25 T 10.1 2.6 37.6 1.7 3.4 51 11.6 2.8 38.3 1.9 3.2 54
25 9524 VG 26 P 11.3 3.0 24.8 1.5 3.8 46 11.0 3.1 25.1 1.6 3.5 47
26 9525 VG 27 T 9.4 2.8 23.3 1.3 5.2 39 9.0 2.8 20.1 1.2 5.1 37
27 9526 VG 29 P 8.8 3.6 37.0 1.5 6.4 42 9.0 3.5 36.9 1.6 6.0 45
28 9527 VG 21 P 15.3 3.9 38.6 1.9 2.3 63 16.1 4.0 38.9 2.0 2.1 64
29 9528 VG 35 P 9.8 2.7 37.5 1.2 8.9 43 10.0 2.7 37.3 1.1 9.6 40
30 9529 VG 32 P 7.0 3.0 33.6 1.4 7.4 36 7.1 3.0 33.7 1.3 7.2 35
31 9530 VG 30 T 13.4 3.4 35.1 1.4 6.6 39 13.6 3.6 36.8 1.5 6.9 40
32 9531 VG 34 T 12.8 3.3 37.6 1.3 9.7 31 13.4 3.5 37.9 1.4 9.3 35
33 9532 VG 27 P 6.7 2.5 35.9 1.5 10.1 28 6.5 2.5 35.7 1.4 11.1 25
34 9533 VG 32 T 10.8 3.3 37.7 1.3 5.6 45 12.4 3.5 37.9 1.5 5.1 48
35 9534 VG 23 T 16.3 4.0 38.6 1.7 3.3 68 17.3 4.3 39.1 2.1 3.1 70
36 9535 VG 36 P 8.1 3.6 37.1 1.3 7.9 38 8.2 3.6 37.5 1.3 8.0 34
37 9536 VG 20 T 10.1 2.7 37.9 1.5 2.9 53 13.5 3.4 38.4 1.7 2.0 61
38 9537 VG 27 P 9.3 2.7 37.5 1.2 4.4 40 8.7 2.7 37.6 1.3 4.5 45
39 9538 VG 29 P 12.8 3.4 38.1 1.5 5.2 45 12.9 3.5 38.3 1.6 5.0 44
40 9539 VG 26 P 11.0 3.2 37.2 1.5 4.2 52 10.1 3.1 37.0 1.4 4.5 53
41 9540 VG 27 T 9.7 2.7 37.6 1.0 5.9 41 10.7 3.4 38.5 1.8 5.2 47
42 9541 VG 28 T 8.1 3.5 38.1 1.6 4.3 50 13.0 3.6 38.4 1.6 4.0 67
43 9542 VG 26 P 11.6 2.8 37.6 1.3 3.9 59 12.0 2.9 37.9 1.4 4.0 57
44 9543 VG 33 T 7.4 2.6 36.1 1.5 8.0 32 9.7 2.8 37.6 1.7 7.4 42
45 9544 VG 36 T 8.4 3.0 37.9 1.4 10.4 27 9.3 3.1 38.2 1.6 9.6 31
46 9545 VG 20 T 14.7 3.9 38.9 2.0 3.1 71 16.1 4.1 39.3 2.2 3.3 65
47 9546 VG 24 T 10.5 2.8 37.6 1.3 4.9 48 12.3 3.0 38.0 1.5 4.7 51
48 9547 VG 28 T 11.3 3.1 36.8 1.1 5.7 47 13.3 3.5 38.4 1.5 5.2 57
49 9548 VG 24 P 9.4 2.7 37.6 1.3 4.5 37 9.5 2.7 37.5 1.3 4.5 36
50 9549 VG 39 P 6.7 2.5 35.1 0.9 11.7 31 6.4 2.4 34.8 0.8 10.4 28
ET  Endometrial thickness (mm), SE VI  Sub endometrial vascularity index (calculated index), SE FI  Sub endometrial flow index (calculated index), SE VFI Sub endometrial vascularity flow index 
(calculated index), FSH Follicle stimulating hormone (IU/L), PROG progesterone (nmol/L)
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